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Catanionic surfactant vesicles have gained attention due to their structural 
similarities to liposomes and their robust properties in biological media.  Catanionic 
vesicles are formed from oppositely charged surfactants and can be exploited for 
applications in vaccine production and drug delivery.  The focus of my research has 
been on the preparation, characterization, and application of functionalized catanionic 
surfactant vesicles.  
Chapter 2 describes the preparation and characterization of catanionic vesicles 
containing sodium dodecylbenzenesulfonate (SDBS) and cetyltrimethylammonium 
tosylate (CTAT).  Vesicle solutions were determined to be stable for greater than 6 
months, formed vesicles with two populations of 80 and 160 nm, and had a 
membrane surface charge similar to human cells, -56 mV.  Furthermore, vesicles 
  
were stable between a pH of 2 and 12, in saline solutions up to 0.6 M NaCl, and after 
autoclaving.  Next, I report the loading of various molecules into the vesicle leaflet 
and the characterization of the resulting functionalized systems.  Hydrophobic 
molecules were readily incorporated into the hydrophobic region of the leaflet.  Lipid 
conjugates of hydrophilic molecules were anchored in the vesicle bilayer.    
Chapters 3 and 4 report the loading of biological materials (i.e. 
liposaccharides and proteins) into catanionic vesicles for the development of bacterial 
vaccines.  Initial studies, discussed in Chapter 3, pertain to the loading of the pure 
components lipooligosaccharide (LOS) and C12-Pan DR helper T cell epitope 
(PADRE) conjugate into catanionic vesicles.  A single dose of these vesicles 
generated a large IgG antibody titer in mice.  Next, in Chapter 4, we focus on the 
extraction of cellular membrane components from cells for their direct incorporation 
into catanionic vesicles.  Vesicles were prepared by adding surfactants in the presence 
of Neisseria gonorrhoeae cells.  Vesicle extracts contained pathogen-derived LOS 
F62ΔlgtD and a subset of proteins from the outer membrane of the bacterium, 
including porin and OPA. 
Lastly, Chapter 5 describes catanionic vesicles in drug delivery.  Vesicles 
were loaded with 88 µg/mL of doxorubicin and shown to retain the drug over 15 
days.  Doxorubicin loaded into catanionic vesicles were shown to be less toxic as 
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Chapter 1: Comparison of Catanionic Surfactant Vesicles to 
Conventional Liposomes  
 
1.1  Introduction 
For decades, nanoparticles have been studied for their potential use as drug 
delivery systems because of their stability, biocompatibility, and ability to distribute a 
drug in vivo.  Nanoparticles that incorporate a drug have shown longer circulation time in 
the body, have improved the therapeutic index of the drug, and have decreased side 
effects from the drug.1  Liposomes, or phospholipid vesicles, have achieved status as drug 
carriers due to their ability to encapsulate an aqueous environment and mimic cellular 
membranes.1-6    Liposomal formulations are utilized as targeted drug delivery vehicles, 
biosensors, and vaccines.   
Liposomes were discovered in the 1960’s when Bangham et al. demonstrated that 
double-tailed amphiphilic molecules self-assembled into colloidal vesicles.7  Since their 
discovery, liposomal formulations of clinically approved drugs have been used in drug 
delivery to increase a drug’s solubility and efficacy.  By adding a protective coating, such 
as polyethylene glycol (PEG), to the liposomal surface, circulation time in vivo can be 
further enhanced.  Targeting agents have also been added to liposomes including 
carbohydrates, antibodies, folate, and peptides in order to direct the liposomal carrier to a 
specific tissue.8-11  
Despite their extensive use and success, liposomal preparations have 
shortcomings for drug delivery: 1) their components are costly, 2) their formation 
requires the input of mechanical energy, and 3) the resulting systems are not 
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thermodynamically stable.  Liposomes are kinetically trapped aggregates that eventually 
fuse together to form lamellar phases, thereby releasing their encapsulated materials.4, 12  
In addition, their phospholipid components are chemically unstable, where hydrolysis and 
oxidative degradation occur readily.4  Various improvements have been considered to 
overcome these deficiencies.13  For example, cholesterol has been added to liposomes to 
improve the mechanical properties and flexibility of the bilayer.13 
A more promising alternative to classical liposomes is catanionic surfactant 
vesicles.14  Similar to liposomes, these catanionic surfactant vesicles form a bilayer with 
an aqueous compartment, but in contrast are formed from single-tailed, charged 
surfactant molecules (Figure 1.1).  This system was first reported by Kaler and it has 
many advantages over conventional liposomes.14 Most notably, catanionic vesicles form 
spontaneously from inexpensive materials and are thermodynamically stable for long 
periods of time.  Alternatively, few reports exist that describe the formation of liposomes 
that do not require extensive preparation techniques.15-17  Liposomes are formed by 
reverse-phase evaporation, dehydration-rehydration, ultrasonication, and freeze-thaw 
extrusion.4  The general film method, originally used by Bangham et al., is one of the 





Figure 1.1.  Chemical structures of a phospholipid and anionic and catanionic surfactants 




Controlling surface charge is another characteristic that is extremely important 
when considering in vivo applications for colloids.  Particles with especially low zeta 
potentials will be stable in solution because they are less likely to aggregate.  
Furthermore, highly negatively charged particles will not fuse with cells.  An excess of 
one surfactant is used in the preparation of catanionic vesicles, thereby resulting in 
vesicles with highly charged surfaces.  In the case of anionic-rich catanionic vesicles, the 
resulting negatively charged bilayer carries a charge similar to a eukaryotic cell and 
should not aggregate with other vesicles in solution.  Many liposomes, on the other hand, 
are prepared from neutral phospholipids and exhibit a zeta potential of zero.18  It is 
therefore not surprising that within the last decade, research using catanionic surfactant 
vesicles has increased significantly, with dozens of catanionic mixtures being studied.19-36 
A detailed comparison between the properties of catanionic vesicles and 
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 In order to understand how catanionic vesicles spontaneously form, are stable, 
and have high encapsulation efficiencies, the properties and capabilities of catanionic will 
be discussed in more detail.   
 
1.2  Physical Properties of Surfactants 
Hydrocarbon-based amphiphiles, referred to as surfactants, are the constituents of 
catanionic surfactant vesicles and are extensively used in commercial applications such 
as textiles, paint products, cosmetics, and soaps.13  These amphiphilic molecules either 
orient their hydrophilic head group or hydrophobic tail toward a polar or nonpolar 
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solvent, respectively.  Depending on the charge of the head group, surfactants are 
considered anionic, cationic, nonionic, or zwitterionic.  
The term “surfactant” originates from surface-active agents and their unique 
ability to form aggregates at the air/solvent interface in order to minimize hydrophobic 
interactions with water (Figure 1.2, A).  When surfactants are added to water, the surface 
tension is lowered as tails assemble in one-direction at the interface.  After maximum 
saturation is achieved at the surface, addition of any excess surfactant only leads to the 
formation of micelles (Figure 1.2, C).  At this point, known as the critical micelle 
concentration (cmc), aggregates form where tails assemble a lipophilic core.  This 
aggregate structure minimizes the interaction between the hydrophobic tails with water.   
 
 
                A               B    C 
        Micelles 
Figure 1.2. Critical micelle concentration (cmc) in solution.  Surfactant molecules are 




Geometric considerations of amphiphiles influence the type of aggregates and 
ordered-structures that will form in solution (Table 1.2).  Depending on the cross-
sectional area of the head group and tail, the packing of amphiphiles controls the type of 
aggregate that forms.13 This principle is introduced by the packing parameter, P, defined 
as: 







                                            Eq. 1.1 
where ν is the volume of the tail, ao(head)  is the area of the head group, ao(tail) is the area of 
the tail,  and l is the optimal chain length (Figure 1.3).37   
Highly curved structures ultimately form when ao(head) > ao(tail).  Depending on the 
ratio of the head group and tail areas, spherical micelles, cylindrical micelles, or vesicles 
form under aqueous conditions.  When both head and tail regions are comparable in size, 
bilayers (i.e. lamellar phases) are most stable.  As the tail becomes far larger than the 
head (ao(head) << ao(tail)), structures with inverse curvature, such as inverse micelles, form 






















































Table 1.2. Effect of amphiphile geometry on aggregate structure.  Estimate of packing 
parameters for amphiphiles leads to the most likely formed structure in solution.  Table 




The phospholipid components of liposomes have two tails and head group of 
comparable size, where P ≈ 1 (Table 1.2).  Therefore, bilayers are the most favorable 
structures for phospholipid aggregates.  In order to form spherical liposomes, 
phospholipids must be forced into their curved aggregate structures, and as a result, are 
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not thermodynamically favorable.  For this reason, liposomes eventually revert back to 




   CTAT  
Figure 1.3. Hydrophobic and hydrophilic moieties on amphiphiles.  The structure of a 




In the case of catanionic surfactant vesicles, individual single-tailed surfactant 
molecules are cone-like in geometry, where P ≈ 1/3 (Table 1.2).  Differential to their 
individual counterparts, the polar portion of cationic and anionic surfactants associate 
with one another to form a zwitterion head group with two tails.  This ion pairing of 
surfactants mimics the characteristic nature of phospholipids (Figure 1.4).  Thus, ao(head) 
is reduced due to the electrostatic interactions of head groups and ν is increased by the 
addition of a second tail, resulting in P ≈ 1.37   One would therefore expect catanionic 
surfactant vesicles to be similar to liposomes with regard to their formation and stability.  
Yet, catanionic surfactant vesicles spontaneously form and are thermodynamically stable.   
 
1.3  Formation of Catanionic Surfactant Vesicles 
Spontaneous formation of catanionic vesicles cannot be explained by merely 
considering their electrostatic and geometric characteristics.  Extensive studies on the 
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phase behavior of catanionic vesicles have revealed that an excess of one surfactant must 
be present in order to spontaneously form vesicles.14, 37-45  The excess of one surfactant 
causes spontaneous curvature of catanionic vesicles where the inner and outer monolayer 
are equal and opposite in curvature (Figure 1.4).  Each leaflet of the resulting curved 
bilayer has a different composition.  A higher mole fraction of the excess surfactant leads 
to less efficient packing and causes the outer leaflet to have a larger head group spacing.  
As a result, the inner leaflet is composed of ion pairs, thereby reducing the head group 
separation, leading to inverse curvature.   
 
       
 
Figure 1.4. Association of cationic and anionic surfactants.  One surfactant must be in 




Differences in the composition of the bilayer results in the ability to control 
surface charge and the zeta potential of the resulting colloidal solutions.  For example, 
catanionic vesicles containing an excess of the anionic surfactant form highly negatively 
charged surfaces.  The highly charge surface prevents aggregation of anionic-rich 




For the original surfactant system studied by Kaler, optimal vesicle formation 
occurs at 7:3 and 3:7 w/w of the cationic surfactant cetyltrimethylammonium tosylate 
(CTAT) and anionic surfactant sodium dodecylbenzenesulfonate (SDBS), respectively 
(Figure 1.5).  By using 1-3 wt % total concentration of the two surfactants with water, 
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The critical aggregation concentration (cac) of catanionic vesicles is far lower 
than the cmc of either of the pure surfactant in water.  For example, solutions of CTAT 
form rod-like micelles at a cmc of 0.01 wt % while SDBS forms spherical micelles at a 
cmc of 0.1 wt %.  Surface tension measurements show that a mixture of SDBS/CTAT 
gives rise to a cac of 0.00017 wt %.  Therefore, the combination of components, where 
one surfactant is in excess, forms more favorable structures compared to individual 




     
Figure 1.6. Phase diagram of CTAT/SDBS in water. Vesicles are present in the two 
lobes, denoted by V+ for CTAT-rich vesicles and V- for SDBS-rich vesicles. The bottom 
axis is the weight ratio of the surfactants and the side axes indicate a total concentration 




Others have built upon Kaler’s work by studying surfactants of various chain 
lengths with a variety of ionic head groups.37, 39-41, 43, 44, 47-49  For example, Regev and 
coworkers showed that the relative length of alkyl chains affects self-assembly, forming 
either micelles, planar bilayers, or vesicles.37  As a result, the quantities needed for each 
surfactant to form vesicles changes as the chain length is adjusted.23 
 
1.4  Loading of Catanionic Surfactant Vesicles 
Catanionic surfactant vesicles have the potential to be loaded with a variety of 
molecules and used as alternatives over conventional liposomes due to their facile 
preparation and ready functionalization with additional components.21-23, 27  Since Kaler’s 
initial work on loading SDBS/CTAT vesicles with glucose14, efforts have expanded to 
improve the loading of molecules into catanionic systems.  While the authors report a 




As seen in the three-dimensional structure (Figure 1.1), the vesicle bilayer 
surrounds an internal aqueous cavity, which has been utilized for the encapsulation of 
water-soluble molecules.  Caillet found that only 0.2% of glucose could be encapsulated 
in catanionic vesicles composed of sodium octyl sulfate (SOS) and 
cetyltrimethylammonium bromide (CTAB).  The authors tried loading other 
biomolecules, but found that only 0.4% of riboflavin could be loaded and 
carboxyfluorescein (CF) could not be encapsulated.47  Other work using SDBS/CTAT 
vesicles revealed that glucose leaks out over time, thereby reducing the promise of 
loading the internal aqueous cavity of catanionic vesicles.19  
Danoff et al. showed that the encapsulation efficiency of SDBS/CTAT vesicles 
was improved by loading a molecule opposite in charge with the vesicle surface charge.35 
Specifically, negatively charged vesicles were found to selectively encapsulate cationic 
dyes and positively charged vesicles selectively encapsulate anionic dyes.36  SDBS-rich 
(anionic) vesicles were loaded with the cationic dye rhodamine B and anionic dye CF.  
Purification of vesicles by gel filtration showed retention of rhodamine B in vesicles 
while CF was separated from the vesicle solution.  Therefore, catanionic vesicles 
preferentially sequester molecules of opposite charge (Figure 1.7).  In contrast, similarly 
charged molecules are inefficiently incorporated into catanionic vesicles due to 
electrostatic repulsion with the vesicle bilayer.36  Further studies showed the successful 











Although catanionic vesicles can be modified by the incorporation of molecules 
using electrostatic interactions, charged molecules can eventually detach or be replaced 
by molecules that bind more efficiently.  An alternative method is to functionalize 
surfactant vesicles by adding a hydrophobic linker to molecules of interest. Using the 
hydrophobic effect, long alkyl chains are inserted into the vesicle bilayer to reduce 
unfavorable interactions in an aqueous environment (Figure 1.8).  As a result, vesicles 
can be functionalized with virtually any molecule that contains a hydrophobic moiety.  
The first realization of this idea was by Walker and Zasadzinski when they functionalized 
the outer membrane of catanionic vesicles with biotin-lipid conjugates.20 PEG has also 
been inserted into the bilayer of catanionic surfactant vesicles in order to improve their 
circulation time in vivo.38, 50  Modification of the bilayer with PEG provides a lipophilic 
barrier that prevents immune system recognition and clearance of vesicles by the renal 
system.2  
 




Catanionic vesicles have also been prepared with glycoconjugates, where the 
carbohydrate is modified with a lipid tail.51-53  Functionalization of catanionic vesicles 
with glycoconjugates is particularly useful due to the involvement of carbohydrates in 
cell-cell adhesion, cell-cell signaling, and the immune response.54  Furthermore, 
catanionic vesicles coated with specific carbohydrates can regulate cell recognition, 
allowing for the targeted delivery of payloads.  The DeShong group reported the 
functionalization of SDBS-rich vesicles with the glycoconjugates glucose, maltose, 
maltotriose, and lactose.33  Carbohydrates were proven to remain accessible by 
performing lectin-binding studies.  Vesicles containing a monomer specific to a lectin 
selectively aggregated after the addition of the lectin.33  
Catanionic vesicles can also be used for in vitro technology as diagnostic agents.  
The Raghavan and Payne et al. have adhered catanionic surfactant vesicles to a surface 
coated with hydrophobically-modified chitosan (HM chitosan) (Figure 1.9).55  The 
hydrocarbon tails on the HM chitosan surface insert into the vesicle leaflet and anchor the 
vesicles.  Functionalized catanionic vesicles anchored to a surface have also shown 
selective binding with molecules in solution.31  Biotinylated catanionic vesicles were 
treated with fluorescently-labeled NeutrAvidin, which has a high binding affinity for 
biotin.  Fluorescence of the tetramer NeutrAvidin remained associated with the anchored 
catanionic vesicles after washing.  These results showed that biotinylated vesicle binding 









1.5  Conclusions 
As previously indicated, the benefits of synthesizing catanionic vesicles include 
lower cost, ease of synthesis, and significantly enhanced vesicle stability.  In order to 
understand and determine the usefulness of catanionic surfactant vesicles in biological 
applications, their loading and stability must first be researched.  If catanionic vesicles 
are to be used over conventional liposomes, they must have similar loading qualities, as 
well as enhanced stability, cost, and ease of preparation.  
 
1.6  Research Goals 
Research in the DeShong group has focused on functionalizing catanionic 
surfactant vesicles for vaccine development and targeted delivery applications.  
Accordingly, it is critical that the methods of preparing functionalized vesicles can be 
optimized and that the stability of the resulting suspensions be characterized.  The focus 
of this study was 1) to prepare, characterize, and functionalize catanionic surfactant 
vesicles, 2) to use surfactant vesicles to extract biologically active molecules for use in 
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vaccine applications, and 3) to load drug molecules within vesicles for use as drug 
carriers.35, 36, 47, 33  
Toward this goal, catanionic surfactant vesicles were prepared with a wide range 
of bioconjugates and fully characterized.  Results of these studies are discussed in 
Chapter 2.  After full characterization, vesicles were loaded with complex molecules and 
were employed for in vivo applications.  These vesicles systems were studied for their 
potential use in developing bacterial vaccines and will be discussed in Chapter 3.  Finally, 
vesicle systems were incorporated with biologically active materials to determine their 
effectiveness as vaccines and targeted drug delivery vehicles.  These results and studies 
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Chapter 2: Loading and Characterization of Catanionic Surfactant 
Vesicles  
Some parts of this chapter are related to the published article:  
Park, J.; Rader, L. H.; Thomas, G. B.; Danoff, E. J.; English, D. S.; DeShong, P., 
Carbohydrate-functionalized catanionic surfactant vesicles: preparation and lectin-
binding studies. Soft Matter 2008, 4 (9), 1916-1921. 
 
 
2.1  Introduction  
Since the discovery of catanionic surfactant vesicles, research has been performed 
on the loading and modification of these systems using dyes, drugs, and functionalizable 
materials.1-8  For example, Walker and Zasadzinski added biotinylated phospholipids to 
the external leaflet of SDBS/CTAT vesicles.3, 9  By hydrophobic interactions, the biotin-
lipid tail associated itself into the membrane of vesicles, thereby decorating the surface 
with biotin.3  To determine the accessibility of biotin for binding, streptavidin, a protein 
that has a high binding affinity for biotin, was added.  Addition of streptavidin induced 
biotinylated vesicles to aggregate in solution (Figure 2.1).   
 
 
Figure 2.1. Biotinylated catanionic surfactant vesicle binding with streptavidin.  Binding 
of streptavidin to biotin leads to vesicle aggregation.  
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The DeShong group has shown that glucose, lactose, maltose, and maltotriose 
were incorporated (18-25%) into the outer leaflet of vesicles by conjugating molecules 
with a hydrophobic moiety employing glycosyl linkages.7  Once glycoconjugates 
inserted, lectins, proteins that are highly specific for carbohydrates, were added.  The 
accessibility of carbohydrates was shown by vesicle aggregation (Figure 2.2).  This 
proved that glycoconjugates remained bioactive by selective binding to their lectins.7  For 
example, the tetrameric lectins, concanavalin A (Con A) and peanut agglutinin (PNA) 
selectively bind to glucose residues and galactose residues, respectively.  Vesicles 
containing terminal glucose monomers showed increased aggregation as the 
concentration of Con A was increased, but lacked agglutination after the addition of 
PNA.  Furthermore, bare vesicles and lactose conjugated vesicles showed no significant 
increase in turbidity when titrated with Con A.  
 
 




 Depending on the chemical structure of these glycoconjugates, surface density of 
catanionic vesicles can be controlled.  Thomas et al. showed that N-linked versus O-
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linked glucosyl conjugates (Figure 2.3) showed significant differences in binding to Con 
A.8  The O-linked conjugates exhibited binding kinetics consistent with a Poisson 
distribution of residues on the vesicle surface (Figure 2.3, A).  N-linked conjugates gave 
rates of aggregation that were consistent with the formation of lipid rafts (Figure 2.3, B).  
This behavior of conjugate clustering at the surface of catanionic vesicles is similar to 
what is observed on a solid surface.10  N-linked glycoconjugates have been shown to 
align on gold surfaces where hydrogen bonding facilitates aggregation.10  The same is 
proposed in a lipid bilayer, causing ligand clustering at the surface of vesicles.   
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Functionalization of vesicles with glycoconjugates is particularly useful due to the 
involvement of carbohydrates in numerous biological processes.11  Carbohydrates are 
also useful in vesicle technology because of their high degree of specificity and rapid 
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interaction with  cell surface receptors. Catanionic vesicles coated with specific 
carbohydrate derivatives should elicit an immune response and target to specific tissues.  
These functionalized vesicles would allow for the recognition of catanionic vesicles as 
vaccines and as targeted delivery vehicles. 
 
2.2  Specific Aims, Results, and Discussion 
The specific aims for this research were 1) to develop methods to prepare bare 
catanionic surfactant vesicles and to examine the reproducibility and stability of each 
method, 2) to characterize catanionic vesicles functionalized with carbohydrates, 
peptides, dyes, drugs, and carotenoids, and 3) to study the use of functionalized 
catanionic vesicles in lectin-carbohydrate binding.   
 
2.2.1  Synthesis and Characterization of Bare Catanionic Surfactant Vesicles 
Bare catanionic vesicles were initially prepared according to the Wang procedure: 
dry surfactants were mixed by gently stirring in water and the colloidal solution 
equilibrated for 48 h.5  Vesicle formation was monitored by measuring the average 
hydrodynamic radius using dynamic light scattering (DLS; see Experimental Section for 
details).  Results showed that vesicles formed after 1 h and were essentially the same size 
as vesicle suspensions that were allowed to develop for 48 h (Table 2.1).  These vesicle 
suspensions were also sonicated in a water bath and remained equal in size before and 
after sonication.  This result showed that once all surfactants dissolved, catanionic 
















Table 2.1. Monitoring vesicle equilibrium by DLS over time.  A stock solution of bare 
catanionic vesicles was prepared by stirring the dry surfactants in water for 1 h and 
analyzing the size of vesicles by DLS.  *The standard deviation of all vesicle suspensions 




Next, catanionic vesicles were monitored over an extended period to determine 
their shelf life and thermodynamic stability.  Vesicle suspensions that formed after 1 h 
were comparable in size and opacity to vesicle samples stored for > 6 months. (Table 
2.2).  This result was important because it meant that catanionic vesicles would be stable 













Table 2.2. Monitoring temporal stability of vesicles by DLS.  A stock solution of bare 
catanionic vesicles was analyzed to determine the shelf life of solutions stirred at room 




Hydrodynamic Radius (nm) 
(± < 0.5 nm)* 
1 54  
3 54 
6 55 
24  56 
48 56 
Time 
Hydrodynamic Radius (nm) 
(± < 0.5 nm)* 
1 week 57 
1 month 57 
5 months 58 
8.5 months 57 
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The previously reported sizes of vesicle suspensions only reported the average 
size.  These results did not confirm whether the vesicles that were produced were 
monodisperse.  For example, the average radius cannot be used for polydisperse samples 
because larger particles scatter light to a greater degree than smaller particles, as 
indicated by eq. 2.1. 
€ 
I∝ d6                                       Eq. 2.1 
In other words, if more than one population of vesicles exists, the larger particles will 
contribute more to the hydrodynamic radius measurement. By varying the scattering 
angle in DLS, if more than one size of particles is present, the hydrodynamic radius will 
not remain constant.  For this reason vesicle suspensions were analyzed by multi-angle 
DLS to determine the their polydispersity.   
As vesicle suspensions were analyzed at scattering angles θ 45 to 150, two 
populations of vesicles were observed (Table 2.3).  The hydrodynamic radii of smaller 












Angle Hydrodynamic Radius (nm) 
45 34, 114, 133 
55 32, 101, 102 
65 46 
75 36, 100, 140 
85 58, 40 
95 35, 98, 114 




150 33, 91, 103 
 
Table 2.3. Confirmation of size distribution of bare catanionic vesicles studied by multi-
angle DLS.  A diluted solution of catanionic bare vesicles was studied varying the 




To confirm these two sizes quantitatively, the diffusion coefficient of each 
population was determined.  If the relaxation time is related to the diffusion of vesicles in 
solution, then the decay rate is 




= Dq2                             Eq. 2.2 
where τ is the relaxation of vesicles, q = (4πn/λ) (sinθ/2) is the wavenumber (n is the 
refractive index of the solution, λ is the wavelength of the laser beam, and θ is the 
scattering angle), and D is the diffusion coefficient.  By 1/τ versus q2, the size of the two 
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populations was confirmed.  Assuming Brownian, monodisperse, spherical, non-






                            Eq. 2.3 
where kB is the Boltzmann constant, T is temperature, η is viscosity of the solution, and 
RH is the hydrodynamic radius.  By using the diffusion coefficient in the Stokes-Einstein 
equation, the hydrodynamic radius for each population was determined (Figure 2.4).  The 
diffusion coefficients from the small and large vesicles confirmed that bare catanionic 




Figure 2.4. Confirmation of size distribution of bare catanionic vesicles studies by multi-
angle DLS.  The hydrodynamic radii were calculated to be 40 nm and 89 nm. 
Wavenumber dependence of the decay rate 1/τ of the vesicle diffusion mode in bare 
vesicles at 25 °C. The initial slope yielded a diffusion coefficient D = 5.460 × 10-8 cm2 s-1 
for smaller particles and D = 2.447 × 10-8 cm2 s-1 for larger particles in accordance with 
eq. 3.  The large deviation from linearity at larger wavenumbers is attributed to 
polydispersity of the smaller vesicles. 
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Next, we wanted to determine which population of vesicles dominated.  As the 
scattering angle increased, the amplitude of smaller particles increased and larger 
particles decreased.  This result indicated that by increasing the angle, a greater amount 
of light was scattered by smaller particles.  By plotting the amplitude of vesicles at each 
angle, the distribution of the two populations showed a majority of the smaller particles 
(Figure 2.5).  As seen in Figure 11, the diffusion coefficient for small particles did not fit 
well at large scattering angles.  This result indicated that smaller particles were 
polydisperse.  In contrast, larger particles were fit well to a linear curve, which showed 
that larger particles were monodisperse.  Unfortunately, the precise ratio of each 
population could not be determined unless standard solutions of 80 and 180 nm particles 
are utilized for calibration. 
 
 
Figure 2.5. Amplitude of small and large particle populations as the scattering angle 






While catanionic vesicle size can be determined by DLS, an actual snapshot of 
vesicles in solution would give a more accurate picture.  For this reason, cryogenic-
transmission electron microscopy (cryo-TEM) was used to confirm our measurements 
reported from DLS.   Dr. Douglas English vitrified bare vesicles in liquid ethanol and 
observed vesicle suspensions by cryo-TEM.  The majority of vesicles appeared to be 80 ± 
20 nm (Figure 2.6).  This result matched the data that we reported from multi-angle DLS.  
 
 
Figure 2.6. Cryo-TEM of bare catanionic vesicles (performed by Dr. Douglas English, 
Wichita State University).  The suspension contained two populations, where smaller 




Next, we wanted to further characterize catanionic vesicles to determine other 
factors that are responsible for their stability.  For example, zeta potential measures the 
charge at the surface of particles.  Zeta potential is important with regard to colloidal 
solutions because highly charged particles are less likely to aggregate with one another 
above ± 30 mV (e.g. most cells).  Zeta potentials were taken on bare catanionic vesicles 
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in order to determine the stability of vesicle suspensions.  Zeta potential measurements 
conducted by Dr. Sara Lioi, Dr. Matthew Hurley, and Neeraja Dashaputre showed that 
SDBS-rich (anionic) vesicles were -57 mV.  SDBS-rich vesicles contain highly 
negatively charged surfaces as a result of an excess of the anionic surfactant SDBS.  
Therefore, SDBS-rich vesicles are stable in solution and will not aggregate because of 
electrostatic repulsion with other vesicles.  Similarly, SDBS-rich vesicles should not fuse 
with cells because of this repulsion.  In contrast, CTAT-rich (cationic) vesicles would 
rapidly fuse with cells as a result of electrostatic attraction.  For this reason, SDBS-rich 
vesicles are the focus of this study.   
Next, we investigated several different vesicle preparation methods in order to 
compare the ease of preparation, reproducibility, scalability, and stability of each method.  
A number of factors influenced the characteristics of the vesicles that were produced.  
These factors included the purity of the initial components, the solubility of the 
surfactants in water or buffer, and the hygroscopic nature of the solid surfactants SDBS 
and CTAT.  Formation of catanionic vesicles was studied using four different methods: 
1) dissolving solid surfactants together in water, 2) blending surfactants together using a 
grinder followed by dissolution in water, 3) combining surfactant solutions, and 4) adding 
solid CTAT to a solution of SDBS.  Specific preparations for each method can be found 
in the Experimental Section.  Each method produced vesicles and each sample of vesicles 
was examined by DLS for their average hydrodynamic radius.  The results from each 
method are summarized in Table 2.4. 
Method 1 demonstrated limited ability for production of catanionic vesicles due to 
the difficulty in precisely weighing small quantities of hygroscopic surfactants.  While 
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solid CTAT is less hygroscopic after recrystallization and can be easily weighed 
reproducibly without restrictions in handling, SDBS becomes gummy from water 
adsorption.  Therefore, a procedure that required reproducible weighing of a hygroscopic 
















Table 2.4. Various sizes of catanionic vesicles prepared by various techniques.  Stock 
solutions of bare catanionic vesicles were prepared by 1) dissolving solid surfactants 
together in water, 2) blending surfactants together using a grinder followed by dissolution 
in water, 3) combining surfactant solutions, and 4) adding solid CTAT to a solution of 
SDBS.  Samples were reanalyzed again after 8.5 months to compare stability to the 
traditional Method 1.  *The standard deviation of unreported vesicle suspensions was < 




Method 2 was not acceptable for the production of vesicles because the resulting 
vesicles lacked reproducibility in size and stability.   Vesicles prepared using this method 
were more opaque than vesicles prepared using solid surfactants, indicating the larger 
size of the vesicles produced by this method.  Since light scattering of larger particles is 
more efficient, the solution containing the larger particles appeared more opaque, as seen 
qualitatively in Figure 15.  More important was that the resulting colloidal solution was 
not thermodynamically stable and after several months the vesicles had precipitated 
(Table 2.4).  The lack of stability and variations in size are likely due to the inaccurate 
Preparation 
Method 
Hydrodynamic Radius (nm) 
(± < 0.5 nm)* 
Initial 
Hydrodynamic Radius (nm) 
(± < 0.5 nm)* 
After 8.5 Months 
1 57 57 
2 146 ± 3 —# 
3 43 40 
4 59 54 
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addition of the required amount of each component.  As seen in the phase diagram for 
SDBS/CTAT, vesicles only form at specific ratios in water (Figure 1.6).  Straying from 
the 7:3 w/w values leads to either precipitation of components or formation of other 
lamellar phases.  In addition, as the surfactants were blended together, the resulting 
mixture became gummy from adsorption of water, which prevented the ability to 
accurately weight out 100 mg of the mixture.  Also, vesicles prepared under this method 




Figure 2.7. Solutions of catanionic bare vesicles formed from 1) solid surfactants and 2) 
blended surfactants.  The University of Maryland seal can be seen behind vesicles 
prepared using dry surfactants.  Vesicles prepared by blended surfactants yielded 
significantly cloudier solutions containing larger vesicles, which scattered light to a 




Method 3 was limited by the solubility of the components and vesicle size.  SDBS 
is readily soluble in water, whereas CTAT is only slightly soluble, which caused 
difficulty preparing stock solutions.  The viscosity of the CTAT solution prevented the 
addition of the CTAT solution to SDBS, leaving residual CTAT in the vial.  Therefore, 
the SDBS solution must always be added directly to the CTAT solution.  Vesicles formed 
immediately upon pipetting the solutions together and remained stable over time.  
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Catanionic vesicles that formed from mixing surfactant solutions were reproducibly 
smaller in size than vesicles prepared under the traditional method of Wang.5  Additional 
studies including multi-angle DLS and cryo-TEM are needed to further characterize 
vesicles made in this manner in order to compare their morphology to vesicles formed 
using Method 1.  However, this method would be appropriate for reproducibility, ease of 
preparation, and scalability of production, assuming that smaller catanionic vesicles were 
required.  
Method 4 was found to produce catanionic vesicles of similar characteristics to 
the traditionally used vesicle forming method.  Catanionic vesicles prepared using either 
Method 1 or Method 4 had comparable properties with regard to their hydrodynamic radii 
(Table 2.4) and stability.  Vesicles prepared using either method produced vesicles with a 
hydrodynamic radius of approximately 56 ± 3 nm.  Suspensions proved to be 
thermodynamically stable in water and vesicle size remained constant over a period of 6 
months at room temperature.  
The average zeta potential was used to determine the electrical potential on the 
surface of the vesicles to determine if these two suspensions were equivalent. Average 
zeta potentials of vesicles prepared using solid surfactants, Method 1, was -57 mV, while 
Method 4 produced vesicles of -56 mV (Table 2.5).   Both preparation methods yielded 
vesicles that were equivalent in size and surface potential, which showed that vesicle 











Table 2.5. Average zeta potentials of bare catanionic surfactant vesicles; performed by 
Dr. Sara Lioi. Solutions of catanionic bare vesicles were formed from 1) solid surfactants 




As indicated earlier, the average hydrodynamic radius does not provide 
information regarding the distribution of vesicle sizes in suspension, but only the average 
size.  Samples prepared by Methods 1 and 4 were analyzed by the English lab.  Both 
suspensions had hydrodynamic radii of ~55 nm and contained two similar populations of 
vesicles (Table 2.6).  Further studies by multi-angle DLS and cryo-TEM would provide 









Table 2.6. Size distribution of vesicles studied by DLS; performed by a student in the 
English group (Wichita State University). Solutions of catanionic bare vesicles were 
formed from (1) solid surfactants and (4) adding solid CTAT to a solution of SDBS, 




Catanionic surfactant vesicles prepared by Methods 1, 3, and 4 were shown to be 
thermodynamically stable while vesicle size was dependent upon the method of 
preparation.  The comparison of different methods for the production of catanionic 
Preparation Method Hydrodynamic Radius (nm) 
1 30-40, 100-130 
4   35-40, 100-150 
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vesicles indicated that vesicle size can be controlled.  Furthermore, different preparation 
methods for vesicle formation may prove more useful than others under special 
conditions.  For example, when loading hydrophobic drugs into vesicles, different vesicle 
preparation methods may incorporate molecules more efficiently.  For example, using 
Method 1, where dry surfactants are dissolved in water, causes difficulty for the 
incorporation of molecules that cannot be solubilized in water.  Whereas Methods 3 and 
4, where a solution of surfactant is prepared, may be used to initially solubilize a drug 
within micelles.  Research has shown that micelles incorporate insoluble molecules inside 
the hydrophobic region of the aggregate.12, 13  After the addition of the second surfactant, 
the hydrophobic molecule may be incorporated into vesicles because of the molecule’s 
association with the initial surfactant.  These methods provide a plethora of opportunities 
to cater to the solubility requirements of individual molecules during loading into 
catanionic vesicles.     
 
2.2.1.1 Stability of Bare Catanionic Surfactant Vesicles under Drug Formation 
Conditions 
In order for vesicles to be considered for in vivo applications, their stability under 
various physiological conditions were studied.  Vesicles were prepared in buffered 
solutions, saline solutions, and tested at different pH values.  Catanionic prepared in 
HEPES buffer at pH 7.4 yielded vesicles of equal size and opacity to vesicle suspensions 
prepared in water.  Specifically, vesicles had a hydrodynamic radius of 55 nm and 
remained this size over time.  Previous studies report that catanionic vesicles remained 
intact after the addition of NaCl solutions.  Vesicles even remained stable beyond 
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physiological saline concentrations (0.15 M).6  Next, solutions of HCl and NaOH were 
added dropwise to vesicle suspensions.  Vesicles remained intact at a pH of 2 to 11 and 
remained equivalent in size at each pH.  These results indicated that catanionic vesicles 
are robust systems that are stable at high ionic strength and extreme pH.  
Next, the long-term storage of vesicles at -20 °C was studied.  Vesicle 
suspensions were frozen in a -20 °C freezer and in liquid N2.  After immediate freezing of 
both samples, surfactants precipitated and the suspensions were no longer cloudy and 
opalescent.  Even upon standing, the bare catanionic vesicles that eventually formed from 
freezing at -20 °C and in liquid N2 had hydrodynamic radii of 195 ± 5 nm and 358 ± 14 
nm, respectively.  These results indicated that vesicles were disrupted and freezing likely 
ruptured vesicles upon formation of ice crystals. 
 Next, we studied the ability to sterilize vesicle suspensions by removing bacterial 
contamination for their potential use in clinical applications.  We sterilized vesicles by 
filtration through sterile filters (0.22 µm) and by autoclaving.  The hydrodynamic radius 
before and after filtration was 57 and 56 nm, respectively.  While vesicle size did not 
change, shearing forces of the vesicles could be an issue if there are ever vesicles larger 
than the membrane.  This would release free surfactant into solution and cause toxicity of 
the surfactant that is not associated with vesicles.  Autoclaved vesicle suspensions 
remained opaque and appeared to be intact, yet increased in size slightly (Table 2.7).  
Since the size of vesicles changed, vesicles may be disrupted under these conditions and 
reform upon cooling and a decrease in pressure.  Further studies were conducted with 
loaded materials in order to determine whether vesicles were disrupted during 





Hydrodynamic Radius (nm) 
 
           Non-sterile                             Sterile 
Bare Vesicles 87 ± 3 114 ± 3 
 
Table 2.7. Purified vesicle-containing fractions by SEC before and after autoclaving.  
Samples were analyzed by DLS to determine whether vesicles were present and to 




While the stability and robustness of bare catanionic vesicles has been reported, 
vesicles require disruption for certain studies.  For example, absorbance measurements 
cannot be conducted in the presence of catanionic vesicles due to their light scattering.  
For this reason, we studied disruption of vesicles by addition of different solvents.  
Gradual addition of ethanol to vesicle solutions disrupted the vesicle suspensions.  
Qualitatively, one could see the disruption since the turbidity of the colloidal suspension 
disappeared (Figure 2.8).  Quantitatively, the intensity of catanionic vesicles measured by 
DLS diminished after the addition of 1 mL of ethanol to 1 mL of a vesicle suspension 
(Figure 2.9).  This disruption method is effective when absorption measurements are 






Figure 2.8. Cloudy vesicle suspensions compared to vesicles disrupted with ethanol 
Catanionic vesicle suspensions were cloudy due to light scattering compared to vesicles 
disrupted with ethanol.  Vesicles initially scattered light and after the addition of ethanol, 
the solution became clear and colorless.  Vesicles were broken and surfactants formed 






Figure 2.9. DLS intensity of a 1 mL colloidal solution of catanionic vesicles disrupted 
with an increasing volume of ethanol.  Decreasing intensity resulted from the decrease in 






 The studies described above indicated that unfunctionalized (bare) SDBS-rich 
catanionic vesicles were prepared reproducibly and that the resulting suspensions 
exhibited excellent long-term stability.  For vaccine production or drug delivery 
applications, functionalized, SDBS-rich catanionic vesicles would be required.  
Accordingly, we extended our study of vesicle stability to these systems.  The major 
questions to be addressed were 1) whether vesicles could be loaded with molecules 
containing various properties, 2) whether vesicles could be characterized to determine the 
amount conjugate incorporated and the size of the resulting suspensions, and 3) whether 
the surface of the conjugates remained active. 
 
2.2.2  Surface Functionalization and Characterization of Catanionic Vesicles  
Catanionic surfactant vesicles have been functionalized and loaded with a variety 
of molecules with the aim to study them in biological processes.  We studied the 
incorporation of hydrophilic and hydrophobic molecules, molecules containing a 
hydrophobic linker, and charged molecules into catanionic vesicles (Figure 2.10).  For 
hydrophilic molecules, it was necessary to attach a hydrophobic linker that would embed 
itself into the leaflet.  This generalized strategy was successfully applied to the 
functionalization of catanionic vesicles with of carbohydrates, peptides, dyes, drugs, and 







Figure 2.10. Vesicles modified with molecules that insert via different mechanisms.  
Representation of hydrophilic, hydrophobic, charged, and conjugated molecules and their 
incorporation into catanionic vesicles.   
 
 
2.2.2.1 Carbohydrate Functionalized Catanionic Vesicles  
Catanionic vesicles were loaded with glycoconjugates (i.e. C12-glucose, C8-
glucose, C8-maltose and C8-maltotriose) that contained an alkyl chain (Figure 2.11) that 
inserted into the bilayer.  Functionalized vesicles were purified by size exclusion 
chromatography (SEC) to purify excess glycoconjugate from vesicles.  Vesicle-
containing fractions were determined by DLS, where fractions 3 and 4 showed the 

























































C8-Maltose       C8-Maltotriose  
 
Figure 2.11. Glycoconjugates functionalized to vesicles C12-glucose, C8-glucose, C8-




A colorimetric phenol/sulfuric acid analysis was performed for each fraction in 
order to detect carbohydrate. Vesicle-containing fractions, 3 and 4, as well as later 
fractions, primarily 9 and 10, turned yellow in color (Figure 2.12, red dashed line).  This 
result showed that glycoconjugate was successfully incorporated into vesicles (Table 2.8) 
and that any unincorporated glycoconjugate was removed. 
 
 
Figure 2.12. Results from SEC carbohydrate-functionalized catanionic vesicles evaluated 
by DLS and colorimetric assay of carbohydrate-loaded vesicles.  SEC fractions were 
evaluated by DLS (solid black line) to identify vesicle-containing fractions.  Fractions 
containing carbohydrates were identified with colorimetric detection at 490 nm (dashed 






















Table 2.8. Glycoconjugate incorporation into catanionic vesicles and DLS results. 
#Incorporation percentage is the fraction of a 1 mM solution of glycoconjugate that eluted 
with vesicles during SEC.  Hydrodynamic radii were determined by DLS prior to SEC. 
*The standard deviation of all vesicle suspensions were < 0.5 nm. 
 
 
 Next, we wanted to determine if the glycoconjugates that were loaded into 
catanionic vesicles remained accessible at the surface.  Carbohydrate functionalized 
vesicles were incubated with a sugar-binding protein, lectin, to determine if the anchored 
glycoconjugates will bind.  The lectin concanavalin A (Con A), derived from the jack 
bean plant (Conavalia ensiformis), selectively binds to glucose monosaccharides.14, 15  In 
this case, binding of the lectin to its cognate sugar should lead to the aggregation of the 
vesicles.  After the addition of Con A to vesicles containing terminal glucose monomer 
units (Figure 2.13), the turbidity of the suspension increased.  These turbid solutions 
indicated that vesicles bound to the lectin and caused aggregation with other vesicles 
(Figure 2.12).   
 Next, we studied the binding kinetics of Con A vesicle aggregation in solution.  
Specifically, we studied the effect of glucose monomer length (monosaccharide, 
disaccharide, and trisaccharide) on the rate of carbohydrate binding.  Con A was added to 
vesicles functionalized with glucose, maltose, and maltotriose conjugates.  Maltose 
showed the fastest rate of binding while glucose and maltotriose were comparable to one 
Glycoconjugates 
Hydrodynamic Radius (nm) 
(± < 0.5 nm)* 
Percent 
Incorporation#  
C8-Glucose 81  18 
C8-Maltose 70 25 
C8-Maltotriose 58 19 
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another (Table 2.9).  The trisaccharide showed the least binding to Con A.  This result 
indicated that the number of monomer units or length of the polysaccharide did not make 
the carbohydrate more accessible to lectin binding.  Since maltotriose contained the most 
monomer units, the trisaccharide flexibility may have decreased the likelihood of lectin 
binding.  Maltotriose may interact with the bilayer or fold back onto itself, thus causing 
decreased binding at the terminal glucose unit.  Furthermore, C8-maltotriose showed a 
smaller hydrodynamic radius than the other glycoconjugated vesicles (Table 2.8).  
Measurement of the hydrodynamic radius of the catanionic vesicles by DLS includes 
molecules protruding from the surface of vesicles.  Maltotriose vesicles were of smaller 
size, indicating that maltotriose is not as elongated as one would expect compared to the 
shorter glycoconjugates.  We hypothesized that maltose showed the fastest and greatest 
binding capability because the disaccharide extends from the surface.  These results 







Figure 2.13. Effect of carbohydrate subunit length on Con A agglutination.  Samples 
were studied at RT by turbidity as a function of time, [Con A] = 5 µM (see Experimental 













Table 2.9. Initial rate of vesicle agglutination at RT using [Con A] = 5 µM (see 
Experimental Section for details).   
 
 
 Next, we wanted to get a snapshot of Con A-vesicle binding.  Catanionic C12-
glucose functionalized vesicles were also examined with and without Con A using cryo-
TEM by the English group.  Images showed that vesicles aggregated and even fused after 
the addition of Con A (Figure 2.14).  Furthermore, vesicles appeared to form multi-
lamellar structures.  These studies with glycoconjugated vesicles shows their ability 
Glycoconjugates Initial Rate (Abs s-1) 






toward the targetability of catanionic vesicles to cell receptors for antigen recognition in 
vaccines and targeted drug delivery vehicles. 
 
Con A + Ves {Ves - Con A} + Ves {Ves - Con A - Ves}
step 1 step 2
 
Scheme 2.1. Binding scheme for Con A-induced vesicle aggregation.8 
 




Figure 2.14. Representative cryo-TEM micrographs of vesicles with C12-glucose. (A) 
Before mixing with Con A the vesicles were unilamellar and spherical.  (B) After mixing 
with 10 µM Con A the vesicles aggregated and became multilamellar.  Experiment 
performed by Dr. English and was taken from ref. 8. 
 
  
2.2.2.1.1 Stability of Carbohydrate Functionalized Catanionic Surfactant Vesicles 
 Subsequently, we wanted to determine if functionalized vesicles had the same 
stability as bare catanionic vesicles under various conditions.  C12-glucose vesicles were 
prepared and their stability was studied in saline solutions and after autoclaving.  C12-
glucose vesicles were prepared at different mole fractions and solutions of increasing 
concentrations of NaCl were added to each sample.  All mole fractions of C12-glucose 
vesicles remained stable at physiological saline, but became unstable at higher saline 
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concentrations of 1.2 M and eventually precipitated (Table 2.10).  This result showed that 
the size remained the same for both functionalized and bared vesicles even when 















Table 2.10. Hydrodynamic radius (nm) of C12-Glucose vesicles at increasing NaCl 
concentrations analyzed by DLS. *The standard deviation of all unreported vesicle 




 As discussed earlier, bare vesicles increased in size after being autoclaved.  This 
increase in vesicle size could have resulted from breaking and reforming vesicles.  To 
study this hypothesis, C12-glucose vesicles were autoclaved to determine if carbohydrate 
was retained.  C12-glucose vesicles were purified by SEC.  Two aliquots were taken from 
vesicle-containing fractions; one sample was autoclaved while the other served as a 
control.  Each sample was purified a second time by SEC to determine if glucose leaked 
out with or without autoclaving.  After autoclaving, carbohydrate-conjugated vesicles 
increased in size (Table 2.11).  In addition, no excess carbohydrate was seen in later 
fractions of SEC (Figure 2.15).  This result showed that even though the size of C12-
NaCl concentration* 
Mole fraction 
0 M 0.15 M 0.3 M 0.6 M 1.2 M 
0.05 80 64 64 62 206 ± 5 
0.1  73  58 57 63 166 ± 3 
0.2 81 61 61 67 252 ± 7 
0.3  77 62  61 65 262 ± 7 
0.4 67 64 64 62 206 ± 5 
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glucose vesicles changed after being autoclaved, the autoclaved vesicles retained 
carbohydrate as efficiently as unsterilized vesicles.     
 
Sample 
Hydrodynamic Radius (nm) 
 
           Non-sterile                             Sterile 
Bare Vesicles 87 ± 3 114 ± 3 
0.01 mf C12-
Glucose 99 ± 2 158 ± 3  
 
Table 2.11. Purified vesicle-containing fractions before and after autoclaving.  Samples 






Figure 2.15. Comparison of sterile and non-sterile C12-glucose vesicles’ second 







2.2.2.2 Loading of Peptides and Chromophores into Catanionic Vesicles 
 At this point, we have demonstrated that hydrophilic carbohydrate derivatives 
required the attachment of a hydrophobic tail before they could be incorporated into 
catanionic vesicles.  Next, we showed that a variety of other molecules could be 
incorporated into catanionic vesicles, including lutein, carboxyfluorescein, maytansine, 
taxol derivative, PADRE peptide-conjugate, and lipid oligosaccharides.  All molecules 
incorporated formed vesicles of similar dimensions and were characterized after 
purification by SEC.  These molecules will be discussed in detail in later chapters.     
 Vesicles were loaded with a 13-mer peptide, PADRE.  Before incorporation of the 
peptide, a hydrophobic linker was added to form a C12-PADRE conjugate (Figure 2.16). 
C12-PADRE conjugate was added to solid SDBS and CTAT and the suspension was 
stirred with water.  Vesicles were purified by SEC and analyzed for the presence of 
peptide using a modified procedure of the Pierce bicinchoninic acid (BCA) assay.16  The 
absorbance was measured at 562 nm and compared to a bovine serum albumin standard 
curve to determine the total protein concentration in each sample.  Vesicle-containing 
fractions appeared purple in color.  This result indicated the presence of peptide 
conjugate peptide in vesicles that inserted via the hydrophobic linker.  
 
(Ala-Lys-Phe-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-Ala)-C12 
C12-PADRE peptide conjugate  
Figure 2.16. Sequence of C12-PADRE peptide conjugate.  The 13-mer contains a C12 





Vesicles were also loaded with chromophores.  These chromophores contained a 
hydrophobic linker, were charged, or were neutral (Figures 2.17-2.19).  Qualitatively, 
after purification by SEC, vesicle-containing fractions clearly incorporated the 
chromophore and were evident by colored solutions.  However, quantitative 
measurements could not be conducted on vesicles containing a chromophore due to the 
interference of light scattering from the vesicles.  Ethanol was added to all fractions to 
disrupt vesicles and to prevent light scattering.  After disruption, the chromophores were 
detected by UV/VIS.  When a phospholipid component was used, vesicle-containing 
fractions were the only fractions where chromophore was observed.  For example, 
vesicles were prepared with lissamine rhodamine B-lipid.  After purification by SEC, no 
residual dye came through later fractions of the column, but was retained on the top of 
the column (Figure 2.20). This result indicated that not all of the lipid dye was 
incorporated into catanionic vesicles and any remaining lipid dye was insoluble in water.  
Lipid dye retained on the column was removed by washing the column with a surfactant 
solution, solubilizing the molecule in detergent. When a linker was not used, excess dye 







































































BODIPY FL C12 BODIPY C8, C5BODIPY C4, C9
 
Figure 2.17. Chemical structure of chromophores containing a hydrophobic linker. 




































Figure 2.18. Chemical structure of dyes containing a charge.  Rhodamine 6G, 




























Pacitaxel fluorescein derivative  
 
Figure 2.19.  Chemical structure of hydrophobic molecules containing a chromophore.  




Figure 2.20. Absorption of lissamine rhodamine B-lipid vesicles after purification by 
SEC.  Fractions were disrupted with ethanol and the absorbance was measured at 575 nm.  
Pink color in vesicle-containing fractions indicated the presence of lipid dye incorporated 





Removal of surfactant components is also important if molecules loaded into 
vesicles need to be retrieved.  Catanionic vesicle suspensions were disrupted with ethanol 
and added to dialysis tubing placed into water.  As ethanol was removed, vesicles 
reformed, preventing the removal of surfactants.  To alleviate this issue, vesicles were 
disrupted with the addition of the detergent Triton-X 100 and dialyzed in water.  After 
one day, soapy bubbles were still present in the dialysis tubing. The soapy bubbles 
indicated the presence of the detergent.  The sample was also analyzed by UV-VIS, 
which contained a characteristic absorption at 260 nm.  This absorption corresponds to 
the UV chromophore of the surfactant aryl functional groups.  Finally, after additional 




 We have hypothesized that functionalized catanionic vesicles could be used in 
vaccine development and drug delivery for in vivo applications. Vesicles remained intact 
between a pH of 2 to 12 and could be autoclaved without releasing their contents.  
Vesicles have also been functionalized with a variety of materials and characterized 
accordingly.  Their increased stability, ease of preparation, and cost show an 
improvement over conventional liposomes.  These robust properties of catanionic 
surfactant vesicles make them excellent candidates for applications that currently employ 
the use of liposomes. 
 
2.4  Experimental 
2.4.1  General Experimental 
 Thin-layer chromatography (TLC) was performed on 0.25 mm Merck silica-coated 
glass plates treated with a UV-active binder.  Compounds were identified using UV (254 
nm), vanillin/sulfuric acid charring, KMnO4, or iodine detection.   
 Melting points were taken in Kimax soft glass capillary tubes using a Thomas-
Hoover Uni-Melt capillary melting point apparatus equipped with a calibrated 
thermometer. 
 Infrared spectra were recorded on a Nicolet 5DXC FT-IR spectrophotometer. Band  
positions are given in reciprocal centimeters (cm-1) and relative intensities are listed as br  
(broad), s (strong), m (medium) or w (weak).  
 
1H NMR spectra were recorded on a Bruker DRX-400 MHz spectrometer.  
Chemical shifts are reported in parts per million (ppm) relative to the solvent.  Coupling 
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constants (J values) are given in hertz (Hz). Spin multiplicities are indicated by the 
following symbols: s (singlet), d (doublet), t (triplet), q (quartet), or m (multiplet). 
 Absorbance measurements were performed on a CHEM2000-UV-Vis-
spectrometer, Ocean Optics, Inc. and fluorescence measurements on an RF-1501 
Spectrofluorophotometer, Shimadzu.   
TEM samples were viewed using a ZEISS EM 10CA Transmission Electron 
Microscope with an accelerating voltage of 80 KV.  
All chemicals and solvents were purchased from commercial suppliers unless 
otherwise noted.  CTAT was purified by recrystallization from ethanol/acetone and 
yielded white shiny crystals. 
 
2.4.2  Synthesis of Bare Surfactant Vesicles 
Vesicles prepared with a molar excess of SDBS will be referred to as SDBS-rich 
(anionic). The surfactants CTAT and SDBS were monitored by TLC using 7:3 petroleum 
ether/EtOH as the solvent to determine the presence of surfactants.  
Method 1: Anionic surfactant vesicles, 1 wt % total surfactant (26.9 mM total 
surfactant), were prepared by adding 9.90 mL of 18 MΩ Millipore water to 70.0 mg of 
SDBS (0.200 mmol) and 30.0 mg of CTAT (0.0658 mmol) (Scheme 2.1).5  The solution 
was stirred for 60 min.   The resulting colloidal suspension was milky in appearance.  The 
concentration of vesicles was determined to be 0.11 µM by using a bilayer of 3.5 nm, 
which was determine by cryo-TEM (Figure 2.21).8  Vesicles were always prepared using 




Scheme 2.2. Preparation of bare catanionic surfactant vesicles from the solid surfactants 
SDBS and CTAT.  The colloidal suspension of vesicles is cloudy and opalescent in 
appearance.  Vesicles have an overall negative charge on the surface from the resulting 






Figure 2.21. Determination of vesicle concentration in solution.  The total surface area 
per surfactant = 0.48 nm2.3  Analysis is based on using a bilayer measurement of 3.5 nm 
determined by cryo-TEM by Dr. Douglas English.  A cac of 2.5 to 3.0 mM and a 




Three additional methods for vesicle formation were studied:  
Method 2: The surfactants, 7.00 g of SDBS (20.0 mmol) and 3.00 g of CTAT 
(6.58 mmol), were blended in a grinder for 3 min.  Then, 100 mg of the surfactant 
mixture was added to 9.90 mL of water and stirred for 60 min.   
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Method 3: Stock solutions of 0.291 M SDBS (101 mg/mL) and 0.219 M CTAT 
(100 mg/mL) were prepared.  Then, 6.90 mL of the SDBS solution (0.200 mmol) was 
added to 3.0 mL of the CTAT solution (0.0658 mmol) and mixed.   
Method 4: A 0.0203 M stock solution of SDBS (7.07 mg/mL) in water was 
prepared.  Then, 9.90 mL of the SDBS solution (0.200 mmol) was added to 30.0 mg of 
solid CTAT (0.0658 mmol) and stirred for 60 min. 
 
2.4.3  Dynamic Light Scattering  
The mean hydrodynamic radius of vesicles was determined by dynamic light 
scattering (DLS), where a Photocor-FC light scattering device equipped with a 5 mW 
laser (633 nm) was used (Figure 2.22).  All measurements were performed at a 90° 
scattering angle at 25 ºC unless otherwise stated.  An autocorrelation function was used to 
determine the hydrodynamic radius and polydispersity index, assuming a Gaussian 










For multi-angle DLS, samples were made by diluting vesicles in water and then 
submerging the optical cell containing the sample in silicone oil at 25 ºC.  Samples were 
allowed to equilibrate for at least 30 min before taking a reading.  The scattering angles 
were varied from 45° to 150° and samples were run for 5 to 10 min.  The intensity auto-
correlation function g2(t) for a single-exponential relaxation mode is 
€ 
g2(t) −1= Aexp(−2Γt)               Eq. 2.4 
where A is the amplitude, t is the lag time, and Γ is the decay rate related to the relaxation 
time τ of the fluctuations by Γ = 1/τ.  
 
2.4.4  Sonication of Bare Vesicles 
 Bare catanionic vesicles were sonicated in a water bath sonicator (Proequip.com 
3510 Branson) for 5 min at room temperature.  DLS (described below) was taken on the 
sample before and after sonication to determine whether the size of vesicles changed.  
 
2.4.5 Zeta Potential Measurements  
 Zeta potential measurement were analyzed by Dr. Sara Lioi.  Methods for the 
measurements are reported in ref. 19.    
 
2.4.6 Preparation of Catanionic Vesicles in Buffered Solutions 
 Bare catanionic vesicles were prepared according to the methods reported in 2.6.2 
accept with the modification of using buffer instead of water.  A 0.1 M solution of 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer was prepared (pH 7.4) 
and was added in the replacement of water. 
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2.4.7 Saline Studies 
 Standard solutions of NaCl were prepared.  Vesicles were prepared under 
different saline concentrations.  DLS was measured on each samples to determine the 
effects of salt concentration on vesicle formation. 
 
2.4.8 pH Studies 
 The pH of vesicles was measured using a standardized pH meter (Denver 
Instrument).  Concentrated HCl (12 M) was added to vesicles to decrease the pH and 
concentrated NaOH (19 M) was added to vesicles to increase the pH.  DLS was 
performed afterward on all vesicle samples to determine the average hydrodynamic 
radius.     
 
2.4.9 Freezing Studies on Bare Catanionic Vesicles 
 A 1 mL vesicle suspension was added to a -20 °C freezer for 1 h or added to 
liquid N2 until the sample froze.  Each sample was removed and warmed to room 
temperature followed by measurements taken by DLS.   
   
2.4.10  Sterilization of Vesicles  
 Vesicles were sterilized using a sterile filter (0.22 µm).  The syringe and filter 
were first rinsed with water followed by the filtration of the vesicle suspension. 
Vesicles were autoclaved at 120°C for 1 h.  Samples were measured by DLS to 
determine their robustness before and after sterilization.   
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Catanionic vesicles were pasteurized by heating vesicle suspensions in a 65 °C 
water bath for 4 h. 
 
2.4.11  Measuring Disruption of Bare Vesicles with Ethanol 
A 1.00 mL portion vesicles was transferred to an empty vial.  Increasing amounts 
of absolute ethanol were added to the vesicle suspension and vortexed.  Each 
ethanol/vesicle mixture was measured by DLS to determine the amount of light scattering 
occurring.  The intensity of light reaching the detector was measured . 
 
2.4.12  Surface Functionalization of Surfactant Vesicles  
To prepare vesicles incorporating glycoconjugates shown in Figure 19, 9.90 mL 
of a 1 mM aqueous solution of glycoconjugate was added to 70.0 mg of SDBS (0.200 
mmol) and 30.0 mg of CTAT (0.0658 mmol) and stirred for 60 min.  Vesicles contained 
glycoconjugate on the inner and outer leaflet (Scheme 2.3).  Vesicles were purified from 
free conjugate by SEC (details reported below).   
To prepare conjugated vesicles with other conjugates shown in Figures 25 – 27, 
the molecule was either weighed directly into a vial or an aliquot was added to the vial, 
followed by removal of the solvent in vacuo.  Then, 70.0 mg of SDBS (0.200 mmol) and 
30.0 mg of CTAT (0.0658 mmol) was weighed into the vial followed by the addition of 
9.90 mL of water and stirring for 60 min. Vesicles were purified from free conjugate by 






Scheme 2.3. Surfactant vesicles functionalized with compounds containing hydrophobic 
moieties via hydrophobic interactions.  Addition of glycoconjugate during vesicles 




2.4.13  Size Exclusion Chromatography 
After vesicle formation, vesicles were purified using size exclusion 
chromatography (SEC), using a column (5.5 cm; 1.5 cm diameter) packed with Sephadex 
G-100 (Sigma).  To the column, 1.00 mL of the colloidal solution was added and 
collected as the first fraction.  Then, 1.00 mL aliquots of Millipore water were added and 
collected in separate vials until the total volume reached 14.00 mL.  After SEC, fractions 
3 and 4 gave the highest intensity of scattered light determined by DLS and therefore, 
corresponded to vesicle containing fractions. 
In the case of functionalized vesicles, samples were analyzed to determine the 
retention of the material by purification a second time through SEC.  A 1.00 mL portion 




2.4.14 Colorimetric Assay for Carbohydrate 
 A colorimetric assay20 using phenol and sulfuric acid was used to detect the 
presence of glycoconjugates in fractions 1-14 from SEC.  A 0.50 mL portion of each SEC 
fraction was transferred to an empty vial where 0.25 mL of 0.530 M aqueous phenol 
(13.3 mmol) was added to the sample, followed by the addition of 1.25 mL of 
concentrated sulfuric acid (18 M) that was introduced as a stream of liquid directly to the 
liquid surface.  The samples were vortexed and allowed to sit at room temperature for 1 h 
to allow the color to develop.  Yellow containing fractions indicated the presence of 
glycoconjugate in solution.  Then, 0.50 mL of ethanol was added and mixed thoroughly.  
After 10 min, the absorbance was measured at 490 nm and compared to a standard curve. 
 
2.4.15  Binding Studies 
Agglutination studies were performed using the lectins concanavalin A (Con A, 
Type V, lyophilized powder) and peanut agglutinin (PNA, lyophilized powder).  Lectin 
stock solutions were prepared by dissolving the lectin in HEPES-buffered saline (HEPES 
10 mM, NaCl 150 mM, CaCl2 1 mM, and MnCl2 1 mM adjusted to pH 7.4 for Con A) 
and (HEPES 10 mM, NaCl 150 mM, CaCl2 1 mM, MnCl2 1 mM, and MgCl2 1 mM 
adjusted to pH 7.4 for PNA) which was incubated overnight.  The resulting solution was 
filtered through a 0.22 µm syringe filter and the absorbance at 280 nm (A280 = 1.37 × [mg 
mL-1 Con A]14, A280 = 0.96 × [mg mL-1 PNA]21) was measured to determine the 
concentration of PNA in solution.   
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For the Con A kinetics binding assay, a 150 µL aliquot of vesicle sample was 
added to a cuvette followed by addition of 150 µL of buffered Con A.  The sample was 
mixed for 5 s and the absorption at 450 nm was measured at 1 s intervals for 30 min. 
 
2.4.16 Transmission Electron Microscopy  
Vesicle-containing fractions from SEC were diluted with water (1:10).  To a 
Formvar Carbon Support Film Mesh 200 (Electron Microscopy Sciences), 3 µL of the 
diluted vesicle sample was added and allowed to dry to a thin film.  Then, 5 µL of 2% 
uranyl acetate stain was applied to the coated grid.  After 30 s, the stain was wicked off to 
form a thin film and was allowed to dry before microscopy.  Samples were then viewed 
by TEM.  These TEM results did not match the vesicle sizes reported by DLS or cryo-
TEM.  Therefore, the size of vesicles changed when suspensions dried to form a thin 
film.  For this reason, cryo-TEM images were performed by Dr. Douglas English and the 
methods can be found in ref. 8 (Figures 14 and 22).  
 
2.4.17  Bicinchoninic Acid Assay for Protein 
Vesicles were also analyzed for the presence of protein using a modified 
procedure of the Pierce bicinchoninic acid (BCA) protein assay (Thermo Scientific) 
(Table 1).16  The working reagent was prepared using a 50:1 v/v ratio of Reagent A 
(sodium carbonate, sodium bicarbonate, bicinchoninic acid, and sodium tartrate in 0.1 M 
sodium hydroxide) to Reagent B (4% copper (II) sulfate).  The test-tube protocol was 
used in which 2.00 mL of working reagent was added to 0.10 mL of the sample.  To 
prevent intact vesicles from scattering light and interfering with the absorbance of 
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samples, 0.10 mL of 1-propanol was added to each sample to break up vesicles.  After the 
addition of the working reagent, the samples were vortexed and incubated at 37 °C in a 
water bath for 30 min.  The absorbance was measured at 562 nm and compared to a 
bovine serum albumin standard curve to determine the total protein concentration in each 
sample.  While each sample was read, the remaining samples were incubated in the 
refrigerator at 4 °C in order to prevent the reaction from progressing further.   
 
2.4.18 Quantifying Dye Incorporation into Catanionic Vesicles 
A 0.50 mL portion of each vesicle fraction was transferred to an empty vial where 
0.50 mL absolute ethanol was added to the sample to prevent light scattering during 
absorption measurements.  Vesicle solutions appeared clear after the addition of ethanol 
(Figure 16).  The samples were vortexed and the absorbance was measured at the 
specified wavelength for the desired molecule.  The absorbance of each chromophore is 
as follows: lutein (446 nm), CF and CF- lipid (500 nm), lissamine rhodamine B-lipid 
(575 nm), doxorubicin (480 nm), and paclitaxel fluorescein derivative (445 nm).    
 
2.4.19  Dialysis 
 Vesicle solutions (1 mL) were added to a dialysis membrane (MW 1,000) and 
equilibrated against 500 mL of water while stirring at room temperature.  Several 
dialyzate changes occurred every several hours and then the solution was left to stir 
overnight.   
 To remove surfactants from solution, vesicles were first disrupted with Triton-X 
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Chapter 3: Loading Complex Carbohydrates and Peptides into 
Catanionic Surfactant Vesicles for Use in Vaccine Applications 
 
3.1  Introduction 
The previous chapter described the preparation and characterization of catanionic 
surfactant vesicles functionalized with simple, small, organic molecules.  We have shown 
that glycolipids could be incorporated into the leaflet of the catanionic vesicle with 
control of both the density and aggregation of the glycolipid.  The goal of the next phase 
of this study was to incorporate multiple bioconjugates (i.e. liposaccharides and peptides) 
into catanionic vesicles.  We were interested in determining whether complex 
bioconjugates loaded into catanionic surfactant vesicles would work toward applications 
in vaccine technology, specifically for the formulation of vaccines against bacterial 
pathogens.  In addition, we studied the ability of loading more than one conjugate 
together during vesicle formation.  This loading would allow for the ability to adjust the 
ratio of each component when controlled addition is required.   
 
3.1.1  Vaccine Formulation 
Currently, the different methods employed for vaccine development include using 
killed pathogens, attenuated strains, inactivated toxoids, and formulated conjugates.1  To 
avoid safety concerns that may arise from attenuated or killed pathogens, protein subunits 
have been employed for viral vaccines.  These proteins are found on the capsid of the 
virus and are utilized to generate an immune response.  In bacterial vaccines, 
carbohydrates are used as antigens. Unfortunately, carbohydrates from the cell surface 
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are poorly immunogenic.  Therefore, a variety of bacterial vaccines have lacked the 
ability to generate effective formulations, including meningitis, gonorrhea, and 
tularemia.1  
 
3.1.2 Bacterial Vaccines 
Efforts toward generating vaccines against pathogenic bacteria include using 
capsular polysaccharides that are specific to their bacterial pathogens.2  For example, 
glycolipids, such as lipopolysaccharide (LPS) or lipooligosaccharide (LOS), are prevalent 
on the exterior cell surface of Gram-negative bacteria.  These antigens play a pivotal role 
in cellular recognition and have been studied in vaccine development.3  For example, the 
lipid A region of liposaccharide has been shown to elicit an immune response (Figure 
3.1).4  For this reason, vaccine formulations have included liposaccharides or lipid A 
alone.  Unfortunately, lipid A is extremely toxic.  However, research has shown that 
incorporating the lipid A of liposaccharides into liposomes greatly reduces its toxicity, 
while still generating an immune response.5-7  Unfortunately, these carbohydrate-based 
vaccines against bacteria are poorly immunogenic and fail to trigger helper-T cell 





Figure 3.1. Chemical structure of lipooligosaccharide components from the Gram-
negative bacteria N. gonorrhoeae.  The various regions include the O-antigen, core, and 




Since polysaccharides are poorly immunogenic, efforts have also been devoted 
toward conjugating carbohydrates directly to large proteins such as tetanus or diphtheria 
toxoids that are known to elicit an immune response.9  However, the inability to control 
the ratio of the carbohydrate antigen to the protein has hampered development in using 
this approach.  
 
3.1.3 Catanionic Surfactant Vesicles as Vaccines 
We were interested in developing carbohydrate-based vaccines against Gram-
negative bacteria, specifically N. gonorrhoeae and F. tularensis by utilizing catanionic 
surfactant vesicles for incorporation of surface antigens onto the outer leaflet. The 
resulting functionalized vesicles would display the antigens on the surface of the vesicle 
in a manner analogous to their presence in bacterial pathogens.  Vaccine studies by our 
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lab were performed using catanionic surfactant vesicles that contained bacterial 
liposaccharides (i.e. LOS and LPS) and Pan DR helper T cell epitope (PADRE) peptide 
conjugate.  The peptide PADRE was chosen for co-incorporation into vesicles because 
the peptide is a synthetic epitope that has been shown to stimulate the production of IgG 
antibodies.10  Specifically, PADRE has been shown to augment the potency of vaccines 
designed to stimulate T-cells in developing a potent immune response against the 
carbohydrate antigens that could be presented.  We undertook this study to determine if 
liposaccharides and PADRE inserted into a catanionic vesicles would be capable of 







Scheme 3.1.  Immune response of LOS vs. C12-PADRE/LOS conjugated catanionic 
vesicles.  Vesicles loaded with only carbohydrate would generate IgM antibodies.  





3.2  Results and Discussion 
3.2.1  Catanionic Vaccines for Neisseria gonorrhoeae  
Surface antigens from Gram-negative bacteria trigger the immune response and 
therefore offer the potential to be used in vaccine development.  Components on the N. 
gonorrhoeae cell membrane that trigger immune stimulation are LOS, porins (PorA and 
PorB), pili, and OPA.11  To date, no one has been able to exploit the immunological 
potential of neisserial LOS as a vaccine candidate.   
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Previous research in the DeShong group utilized LOS from N. gonorrhoeae for its 
incorporation into catanionic vesicles.  In order to avoid toxicity associated with lipid A, 
the lipid A region was cleaved (Scheme 3.2).12  A C12-conjugate was added to the 
oligosaccharide to provide an anchor for insertion into vesicles.  While this method was 
effective when preparing functionalized vesicles, incorporation of the lipid A region into 
liposomes is known to lower its toxicity.  Consequently, we studied vesicles loaded with 
the entire liposaccharide unit to determine if lipid A toxicity is removed after 
incorporation into catanionic systems. 
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Scheme 3.2. Preparation of LOS conjugate from N. gonorrhoeae.  The toxic lipid A 
portion was cleaved from the oligosaccharide using hot acetic acid and a hydrophobic 






Catanionic vesicles were prepared by adding native LOS derived from N. 
gonorrhoeae F62Δ lgtD (a strain that produces lacto-N-neotetraose LOS), which was 
provided by Dr. Daniel Stein’s Group (Figure 3.2).  Addition of this isolated pathogenic 
component should decorate the exterior membrane of vesicles (Scheme 3.1).  Vesicles 
were purified by SEC and the presence of saccharide in the vesicle-containing fractions 
was confirmed using the phenol/sulfuric acid assay (described previously) (Table 3.1).13  
Next, we developed a glycoconjugate-based vaccine (TRIAD) that contained the 
liposaccharide component and an epitope unit that would trigger the immune system.  We 
utilized LOS and Pan DR helper T cell epitope (PADRE) peptide conjugate that 
possesses the ability to bind to a large number of HLA class II molecules.  PADRE 
(Figure 3.3) was coupled with N-dodecanoylsuccinimide to form dodecanoic acid 
tethered PADRE conjugate that inserted into the vesicle bilayer (Scheme 3.3).14 Both 
components were inserted into surfactant vesicles using a 10:1 w/w of LOS and C12-
PADRE, respectively, and were purified by SEC (Scheme 3.4). Vesicle-containing 
fractions were analyzed by the phenol/sulfuric acid carbohydrate assay (described in 
Chapter 2) and by fluorescence. Results confirmed the presence of carbohydrate and 
phenylalanine and tryptophan residues in vesicle-containing fractions from SEC.  These 
catanionic surfactant vesicle formulations were stable at room temperature for years, 
unlike typical liposomal vaccine formulations.  Furthermore, TRIAD is so robust that it 

































































LOS F62Δ lgtD from N. gonorrhoeae  
Figure 3.2. Chemical structure of lipooligosaccharide (LOS) F62Δ lgtD purified from N. 
gonorrhoeae.  O-Antigen: Galβ1-4GlcNAcβ1-3Galβ1-; Core: -4Glcβ1-4Hepα1-(-
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PADRE peptide               C12-PADRE peptide conjugate  
Scheme 3.3. Synthesis of C12-PADRE peptide conjugate.  Conjugated PADRE peptide 








Table 3.1. Average amount of carbohydrate in TRIAD vaccine from two batches.  





Scheme 3.4. Preparation of TRIAD vaccine formulated with catanionic surfactant 
vesicles containing the C12-PADRE peptide conjugate and LOS from N. gonorrhoeae.  
Ratio of conjugate components can be adjusted during vesicle formation to control the 




3.2.1.1 Animal Studies with Vesicle Antigens 
Lindsey Zimmerman in the Stein lab performed immunization studies.  Mice were 
treated with TRIAD vaccine that contained LOS and C12-PADRE at a ratio of 10:1.  
Antibody levels were determined by ELISA immunoassay by immunizing with 2 mg of 
LOS equivalent.  Antibody titers for both LOS and LOS/C12-PADRE vesicles showed the 
generation of antibodies after mice were inoculated.  Treatment with LOS vesicles 
showed that only primary antibodies were present (IgM).  These results indicated that 
only a primary immune response was achieved.  Inoculation with LOS/C12-PADRE 
 Carbohydrate (µg/mL) % Incorporation 
TRIAD 
Vaccine 51 ± 7 96 ± 16 
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showed that our vaccine induced a high titer anti-LOS antibody response, with the 
majority of the elicited antibody being IgG (Table 3.2).  Intraperitoneal immunization of 
mice with our vaccine construct produced no observable adverse effects in mice, while 
intraperitoneal immunization with equivalent amounts of purified LOS induced 
significant adverse effects.  Therefore, catanionic vesicles loaded with LOS/C12-PADRE 
may have generated IgG antibodies that recognize LOS (Scheme 3.1). Immunogenic 
recognition of LOS in our TRIAD carbohydrate-based vaccine and may offer protection 
against N. gonorrhoeae in challenged mice.  Furthermore, the LOS from the strain F62Δ 
lgtD contains the same LOS found in N. meningitidis.  We have not tested protection of 
vaccinated mice against gonorrhea and meningitis, but a vaccine derived from F62Δ lgtD 
LOS could offer protection against both gonorrhea and meningitis.  This would allow a 









Table 3.2. Antibody titer results in mice inoculated with LOS and LOS/ C12-PADRE 




3.2.2 Catanionic Vaccines for Francisella tularensis  
Similar catanionic vaccines were performed in F. tularensia.  Catanionic vesicles 
were prepared in the same manner as reported in section 2.2.1, but native LPS from F. 
 Inoculation Antibody Titer IgG:IgM 
Initial  1:1500 
LOS/PADRE Vesicles 
Booster (2 weeks) 1:2000 
75:25 
LOS Vesicles (Control) Initial 1:100 0:100 
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tularensis was substituted for LOS (Figure 3.4).  Vaccine studies were performed by Dr. 
Stefanie Vogel.  After inoculation of LPS control vesicles, mice challenged with the 
virulent strain of F. tularensis died within four hours.  Conversely, four out of five mice 
inoculated with LPS/C12-PADRE vesicles survived for four days after being challenged.  
One mouse even survived for two weeks. These results showed that mice vaccinated 
using LPS/C12-PADRE vesicles survived longer than the control group. These vaccines 
offer promise toward the development of vesicle-based vaccines to combat tularemia 
infections.  Further vaccine studies are currently underway to determine the antibody 
titers using the ELISA immunoassay. Furthermore, the ratio of peptide conjugate to 
saccharide can be controlled in vesicle-based vaccines in order to control the immune 



































































LPS from F. tularensis  
 




3.3  Conclusions 
We have devised a safe and effective way of generating a large IgG titer against 
carbohydrate with a small dose of vaccine.  A single dose of TRIAD injected 
intraperitoneally induced a robust antibody response against carbohydrate without 
adverse effects.  The generated response was mostly IgG and reached a maximum titer 
with one dose of the vaccine.  We believe that this will allow us to generate a universal 
vaccine capable of protecting against all serotypes of N. meningitidis.  This vaccine 
platform also readily lends itself to further modifications in that it is possible to include 
additional neisserial proteins.  In Chapter 4 we report incorporation of neisserial proteins 
and LOS via a novel whole cell extraction protocol, which offers the ability to load a 
variety of membrane components into vesicles.   
 
3.4  Future Work 
 Vaccine studies will be continued by functionalizing vesicles with other 
liposaccharides and peptides.  By coating surfactant vesicles with liposaccharides from 
the outer envelope of bacteria, vesicles were shown to elicit an immune response as 
mentioned above.  Studies will be performed to determine how much C12-PADRE 
conjugate and liposaccharide can be loaded into vesicles.  Varying ratios of C12-PADRE 
conjugate and liposaccharide will be prepared and tested for antibody titers using ELISA 
analysis.  This work is important because the relative ratio of liposaccharide to peptide 





3.5 Experimental  
 Animal studies were preformed by under the direction of Dr. Daniel Stein in the 
Department of Cell Biology and Molecular Genetics at the University of Maryland and 
Dr. Stefanie Vogel in the Department of Microbiology and Immunology at the University 
of Maryland School of Medicine. 
 
3.5.1  Materials 
All chemicals and solvents were purchased from commercial suppliers unless 
otherwise noted.  CTAT was purified by recrystallization in ethanol/acetone prior to use.  
 









A solution of dodecanoic acid (0.539 mmol, 0.108 g), N-hydroxysuccinimide 
(NHS) (0.573 mmol, 0.0660 g), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC⋅HCl) (0.574 mmol, 0.110 g) in DMF was stirred at room 
temperature for 4 h (Scheme 3.5).  The solution was diluted with ethyl acetate (20 mL) 
and washed with H2O (20 mL), saturated aqueous NaHCO3 (20 mL), and H2O (20 mL x 
2).  The organic layer was dried over MgSO4, filtered, and concentrated in vacuo.  
Purification after recrystallization (diethyl ether/hexane) afforded 0.0977 g (58%) of N-
dodecanoylsuccinimide as white shiny crystals: Rf = 0.85 (diethyl ether/hexane); mp 78 – 
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79 °C (lit.15 78-81°C); IR (thin film, NaCl) 2929 (m), 2852 (m), 1744 (s); 1H NMR 
(CDCl3, 400 MHz) δ 2.84 (s, 4H), δ 2.61 (t, J = 8 Hz, 2H), δ 1.75 (m, J = 8 Hz, 2H), δ 
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Dodecanoic Acid Tethered PADRE Peptide Conjugate  
To a solution of PADRE peptide (Figure 3.4) (GenScript) (1.445 µmol, 1.950 mg, 
2.890 µM) in 0.5 mL of DMSO-d6 was added a solution of N-dodecanoylsuccinimide 
(1.445 µmol, 0.430 mg, 2.89 µM) in 0.5 mL of DMSO-d6 followed by a solution of 
diisopropylethylamine (50 µL, 1.44 µmol, 28.7 mM) in DMSO-d6.  The resulting solution 
was mixed well by vortexing and stirred at room temperature for 24 h. 1H NMR analysis 
of the reaction mixture indicated that approximately 85% of NHS C12-ester was reacted 
with PADRE by comparing the integration of starting material to product.  The reaction 












   PADRE peptide            C12-PADRE peptide conjugate  
 




3.5.3  Isolation and characterization of LOS 
LOS was obtained from Lindsey Zimmerman and Amanda Mahle in the Stein 
Lab.  The LOS was purified from N. gonorrhoeae F62Δ lgtD, a strain genetically 
modified to produce only the lacto-N-neotetraose LOS (L7 immunotype), using a hot 
phenol/water extraction.16 
 
3.5.4 Synthesis and Characterization of Surfactant Vesicles 
Vesicles prepared with a molar excess of SDBS will be referred to as SDBS-rich 
(anionic).  
To prepare vesicles with the liposaccharides shown in Figures 3.3 and 3.4, the 
liposaccharide was weighed directly into a vial containing 70.0 mg of SDBS (0.200 
mmol) and 30.0 mg of CTAT (0.0658 mmol).  Specifically, 1 mg of LOS or LPS and 0.2 
mg of C12-PADRE conjugate were used to give a 10:1 w/w ratio of antigens in vesicles.  
Then 9.90 mL of water was added and samples were stirred for 60 min.  Vesicles were 
purified from free conjugate by SEC, described previously. 
The incorporation of carbohydrate and C12-PADRE-conjugate were determined 
by colorimetric assays to determine the quantity retained in vesicle-containing fractions 
(See Chapter 2 for details).  The phenol/sulfuric acid colorimetric assay is described 
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previously.13  The absorbance was measured at the λmax (~490 nm) and compared to a 
standard curve, prepared for LOS and LPS to determine the total carbohydrate 
concentration in each sample.  
 
3.5.5  Animal Trials 
Mice were immunized by the Stein lab intraperitonealy with either 10 µg of 
purified LOS alone, or 8.5 µg of conjugated vaccine (Vs-OS-PADRE). On day 21 and 42, 
mice were boosted with an equivalent amount of vaccine or oligosaccharide and blood 
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Chapter 4: Methodology for the Extraction of Membrane 
Components from Neisseria gonorrhoeae  
This chapter is taken from the prepared article: 
Stocker, L. H.; Horn, A.; Zimmerman, L.; Dhabaria, A. P.; Fenselau, C.; Stein, D. C; and 
DeShong, P., Extraction of membrane components from Neisseria gonorrhoeae using 
catanionic surfactant vesicles. In preparation. 
 
 
4.1  Introduction 
Cell surface receptors play a crucial role in cell-cell communication and 
recognition.1  In Gram negative bacteria, cell-cell recognition is a key feature of pathogen 
virulence2 and biofilm formation.3  Accordingly, methods for the extraction and 
purification of carbohydrates and proteins from cellular membranes, followed by 
reconstitution of cellular components into stable hydrophobic matrices has been widely 
investigated as a model system for studying surface-mediated phenomena.4-13  Due to the 
complexity of biological membranes, cell surface components are often studied in 
artificial membranes in order to determine their specific role and mechanism of action.12   
However, when solubilizing and reconstituting membrane proteins, special consideration 
must be taken in order to retain the orientation and biological activity of the protein.11  
 
4.1.1  Reconstitution of Membrane Proteins into Liposomes 
There are a number of strategies employed for the insertion of proteins into 
liposomes, including mechanical means, freeze-thaw methods, organic solvent-mediated 
reconstitution, direct incorporation into preformed liposomes, or detergent-mediated 
reconstitution.12, 13  Detergent-mediated reconstitution is the most commonly used 
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method because detergents are often involved during the initial solubilization step for 
cellular membrane proteins.  As outlined in Scheme 4.1, the detergent-mediated 
reconstitution procedure developed by Rigaud begins with the addition of detergent to the 
native membrane to solubilize proteins in a lipid-detergent solution.12, 13  After protein 
purification, excess detergent is removed by dialysis, gel chromatography, or absorption 
onto hydrophobic resins to form a closed lipid vesicle.7  Due to the lipophilic nature, 




Scheme 4.1. Reconstitution of purified membrane proteins into liposomes compared to 
extraction procedure using catanionic vesicles.  Incorporation of membrane components 
into liposomes requires purification, addition of phospholipid, and removal of surfactant.  
Extraction using catanionic surfactants only requires the addition of a second surfactant 






 Other methods of protein incorporation into liposomes have been conducted where 
preformed liposomes are incubated in the presence of cells14 or proteoliposomes.15  One 
study focused on extracting membrane-bound proteins from human erythrocytes by 
incubating cells with sonicated phospholipid liposomes.14  The resulting liposomes were 
shown to contain cell surface proteins by subjecting cells to lactoperoxidase iodination 
prior to incubation with liposomes followed by detection of 125I-labeled proteins in 
liposomal extracts.14  Another study reported the transfer of proteins from 
proteoliposomes into giant unilamellar vesicles (15-120 µm).15  Proteoliposomes were 
prepared and incubated in the presence of giant unilamellar vesicles, where spontaneous 
transfer of a mitochondrial proteins occurred within 24 h.15  
 
4.1.2  Liposomal Bacterial Vaccines 
Outer membrane proteins from bacteria have been incorporated into liposomes for 
vaccines and the immune response of the resulting liposomal preparations has been 
reported.8-10, 16-18 Liposomal formulations of antigens have particularly significant 
advantages in vaccine formulation over cell-based formulations since they avoid safety 
concerns that may arise from attenuated or killed pathogens.  Previous research has 
demonstrated that PorA from Neisseria meningitidis incorporated into liposomes induced 
an immune response against many serotypes of meningococci.17  In a recent study, 
Zollinger et al. reported a liposomal vaccine currently in a Phase I study containing major 
outer membrane proteins from N. meningitidis.10  In this study, surface antigens of N. 
meningitidis were presented in three manners: adhesion to aluminum hydroxide, insertion 
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into proteoliposomes, and insertion into liposomes: the latter preparation gave the most 
effective immune response in humans.10 
Lipopolysaccharide (LPS) present in Gram negative bacteria have been shown to 
act as adjuvants, resulting from the lipid A portion of the molecule.19  While vaccines 
have been formulated that contain LPS or lipid A alone, the toxicity of LPS has limited 
its use in vaccine formulation.20  Incorporating LPS or lipid A into liposomes21-26 has 
been shown to greatly reduce toxicity.27-29  Unfortunately, carbohydrate-based vaccines 
are poorly immunogenic and fail to trigger helper-T cell recognition.30  Therefore, long-
term protection of the carbohydrate is not achieved.  
 
4.1.3  Outer Membrane Vesicles for Vaccines 
Another formulation of bacterial vaccines are outer membrane vesicles (OMV), 
also referred to as blebs.31  OMV bud off from bacterial cells and are comprised of 
several membrane components from the original cell that are incorporated into the OMV 
lipid bilayer structure.  Research has shown that OMV from N. meningitidis generate an 
immune response directed to PorA.32  For example, the commercially available vaccine 
HexaMen is used against bacterial meningitis and is derived from OMV.33 34-36   
 Liposomal formulations of cell surface components have several limitations as 
vehicles for displaying cell surface proteins and lipids in a stable membrane-like 
environment.   First, since cell surface components typically reside in the hydrophobic 
bilayer, the solubilization and purification of these substances from the membrane often 
results in denaturation of the protein.   Second, it is unclear if insertion of the purified 




 Another major limitation of the liposomal formulation approach is related to the 
general physicochemical characteristics of liposomes.  Liposome production requires 
either sonication or passage through a membrane.  This results in the addition of 
mechanical stress to the system that also may lead to denaturation of sensitive biological 
components.  Liposomal preparations prepared by either sonication or membrane 
extrusions are very heterogeneous with respect to size (300 nm to 20 µm).  Finally, 
liposomal formulations are typically unstable in biological media and are 
thermodynamically unstable.  
 
4.1.4  Catanionic Vesicle Bacterial Vaccines 
We have investigated the use of catanionic surfactant vesicles37 to extract 
membrane components from pathogenic bacteria directly into these systems without 
further purification of cellular components (Scheme 4.1).  Most notably, these vesicles 
are formed from inexpensive, commercially available surfactants, form spontaneously 
with only mixing involved, and possess long-term and enhanced stability when compared 
to their liposomal counterparts.38, 39  These properties make them attractive for vaccine 
formulations due to ease of handling, preparation, and storage.   
In this chapter, we describe the extraction of cell surface components from N. 
gonorrhoeae directly into catanionic vesicles.  Mass spectral analysis of the proteins 
contained within these vesicles demonstrated that key cell surface components were 
effectively incorporated into the vesicles.   To our knowledge, this is the first study in 
which membrane components were directly extracted from bacteria into vesicles without 
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purification prior to incorporation into the lipid bilayer structure.  The resulting extraction 
method creates an "artificial pathogen", which can be used for the development of 
vaccines.     
 
4.2  Results and Discussion 
Vesicle extractions of N. gonorrhoeae were prepared using the methods described 
in the Experimental Section.  After purification of catanionic vesicles by column 
chromatography, vesicles were characterized using a colorimetric carbohydrate assay, a 
BCA protein assay, silver staining after gel electrophoresis, Western blotting, and mass 
spectrometry-based proteomics.  The results indicated that membrane components from 
this bacterium were incorporated into catanionic vesicles.  
Five different methods were used to construct the vesicles in order to determine if 
protein and carbohydrate were incorporated better by a specific method (Table 4.1).  
Details for each preparation method can be found in Experimental Section 2.4.2.  After 
purification by gel filtration, the resulting vesicle-containing fractions were tested for the 
presence of carbohydrate and protein using a carbohydrate colorimetric assay39 and the 
BCA protein assay40 (Table 4.1).  While the total amount of protein and carbohydrate 
varied with the purification method, each method was able to incorporate significant 
levels of cellular proteins and carbohydrates.  While these assays quantitatively 
determined the amount of carbohydrate and protein contained within vesicles, they lacked 







Table 4.1. Total protein and carbohydrate concentrations in vesicle extract samples 
determined by colorimetric BCA and carbohydrate assays.  All five extraction methods 
yielded similar quantities of protein and carbohydrate by methods 1) solid surfactants 
added to the bacterial cell pellet followed by the addition of water, 2) SDBS solution 
added to the bacterial cell pellet followed by the addition of a CTAT solution 3) CTAT 
solution added to bacterial cell pellet followed by the addition of solid SDBS 4) SDBS 
solution added to bacterial cell pellet followed by the addition of solid CTAT 5) bare 
vesicles added to the bacterial cell pellet. BCA assay indicated the presence of protein in 




In order to visualize the cellular components incorporated into catanionic vesicles, 
the various vesicle preparations were compared to the whole cell lysate and original cell 
pellet by gel electrophoresis followed by silver staining (Figure 4.1).  The presence of 
LOS in vesicles was suggested by the presence of bands with electrophoretic mobility 
similar to that of purified F62ΔlgtD LOS. We expected LOS to be readily incorporated 
into vesicles because the biophysical properties of Lipid A should be solubilized by the 
lipophilic bilayer.  The distribution of proteins incorporated into the vesicles differed 
from the distribution of proteins obtained from whole cell lysates, suggesting that 
vesicles were only extracting a subset of bacterial proteins (Figure 4.1).  

























All fractions of Method 4 from SEC were analyzed by gel electrophoresis 
followed by silver staining in order to characterize the carbohydrates and proteins that 
were incorporated into the vesicles (Figure 4.2).  These data indicated that numerous 
proteins eluted in the same fraction as intact vesicles, supporting the conclusion that the 
cellular components were incorporated into the vesicles. 
 
 
Figure 4.1. Vesicle-containing fractions purified by gel filtration followed by silver 
staining.  Lanes 1-6 and 9 were loaded with 1 µL, Lane 7 was loaded with 5 µL, and Lane 
8 was loaded with 167 nL of sample and analyzed by SDS-polyacrylamide Tris-tricine 
16.5% v/v gels followed by silver staining.  Lanes 1-6 corresponded to vesicle-containing 
fractions prepared from extraction methods 1-6, respectively, and showed similar protein 
patterns.  Lane 7 showed the purified cell lysate disrupted by SDBS and purified by gel 
filtration.  Lane 8 contained a very different protein pattern from resuspended GC cell 







Figure 4.2. Vesicle extract fractions from gel filtration analyzed by silver staining.  
Lanes were loaded with 1 µL of sample and analyzed by SDS-polyacrylamide Tris-tricine 
16.5% v/v gels followed by silver staining.  Lanes 1 and 2 represent the void volume and 
are free of protein and carbohydrate.  Lanes 3 and 4 correspond to vesicle containing-
fractions and indicate the presence of a range of proteins and a high concentration of the 
carbohydrate LOS F62ΔlgtD with the darkest band at the bottom of the gel.  Lanes 5-14 




Western blotting of the loaded materials from these surfactant vesicles showed the 
presence of LOS and the two predominant membrane proteins porin (36 kD) and Opa 
(25-30 kD) (Figure 4.3).  Mass spectrometry analysis was performed by Dr. Catherine 
Fenselau’s Group on vesicles containing gonococcal cell extracts and identified 157 
gonococcal protein fragments.  This analysis identified many of the known outer 
membrane proteins and membrane associated proteins found in the gonococcus. For 
example, mass spectrometry identified the major outer membrane protein porin P.IB, the 
outer membrane protein PIII, the major lipoprotein, components of the antibiotic 
resistance efflux pump, pilin and proteins associated with pilin assembly, numerous 
transport proteins, and putative two-component transport system proteins.  This analysis 
also identified numerous ribosomal proteins and proteins involved in energy generation.  
These latter proteins, while not components of the outer membrane, represent major 
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Figure 4.3. Western blotting of vesicle-containing fractions, lysate, and supernatant.  The 
purified vesicle extract showed antibody binding to several proteins and LOS, 
specifically porin (36 kD) and OPA (25-30 kD).  The lysate fraction did not show any 




Proteinase K protection experiments were performed to determine if bacterial 
proteins were localized to the interior of the vesicles.  Loaded vesicles were digested with 
proteinase K to determine if proteins associated with vesicles were protected from 
digestion.  Both vesicle samples and the whole cell lysate showed complete digestion 
using this enzyme (Figure 4.4).  Since proteinase K is a nonspecific digestion enzyme, 
these results demonstrated that any protein at the surface of vesicles was digested 
completely by the enzyme.  This proteolytic enzyme does not digest the carbohydrate 





Figure 4.4.  Proteinase K digestion. Lanes 1 and 3 showed the protein pattern of the GC 
lysate and vesicle extract, respectively, after silver staining.  Lanes 2 and 4 contained GC 
lysate and vesicle extract purified by gel filtration and show digestion of all protein bands 




Digestion of vesicles using trypsin gave a different pattern.  Digested proteins in 
the form of peptide units were seen in great concentrations at the bottom of the gel 
(Figure 4.5).  The vesicle samples showed protection for a few proteins, while the whole 
cell lysate fraction was completely cleaved by trypsin.  This indicated that vesicles 
contained proteins embedded in the bilayer, where they are protected from cleavage from 







Figure 4.5.  Protection from trypsin digestion.  Lanes 2 and 3 showed the protein pattern 
of the whole cell lysate before and after digestion with trypsin, respectively.  Lanes 4 and 
6 contained GC lysate and vesicle extract purified by gel filtration, respectively.  Lanes 5 
and 7 showed the protein pattern of GC lysate and vesicle extract after digestion with 
trypsin, respectively.  Digested vesicle extract showed the retention of a few proteins and 




4.3  Conclusions 
This work offered a way to extract membrane components from pathogenic 
bacteria for potential vaccine formulation using catanionic surfactant vesicles.  
Membrane components of a cell would be useful if they could be easily separated.  The 
vesicle extraction procedure introduced here offers potential enrichment of LOS and 
other membrane components from N. gonorrhoeae.  These catanionic vesicles extracts 
are stable at room temperature for prolonged periods of time and offer an improvement 
over proteoliposomes. Furthermore, the structure of LOS involved in the meningococcal 
disease is identical to that expressed by the N. gonorrhoeae F62ΔlgtD used in vesicle 
extractions.  Additional work will be devoted to generating a universal vaccine able to 
protect against all serotypes of N. meningitidis.  The described vesicle extraction is 
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currently being studied for use with other pathogens, including F. tularensis, P. 
aeruginosa, and E. coli.  Vesicle extracts from E. coli are currently being tested in cows 
for vaccination of dairy cow mastitis.   
 
4.4  Experimental 
Animal studies were preformed by under the direction of Dr. Daniel Stein in the 
Department of Cell Biology and Molecular Genetics at the University of Maryland 
covered by Environmental Safety Tracking Number 11-50 (E-946). 
 
4.4.1  General Experimental 
All chemicals and solvents were purchased from commercial suppliers and were 
used as received unless otherwise noted.  All aqueous vesicle solutions were prepared 
from a Millipore (18MΩ) water purification system and all assays used water purified 
using an Elix 5 (Millipore) water purification system unless otherwise stated.  An Ocean 
Optics USB 2000 Spectrometer was used to measure UV-VIS absorbance of samples.   
 
4.4.2  Cell Cultures 
 Cell cultures were grown by Lindsey Zimmerman.  N. gonorrhoeae F62ΔlgtD41 
cells were grown for 48 h to an OD of ~1.0 (650 nm) (109 CFU).  A 20 mL aliquot of 
bacterial cell culture was collected by centrifugation at 9,000 RPM for 30 min and the 





4.4.3  Vesicle Preparation 
Sodium dodecylbenzenesulfonate (SDBS) was purchased from TCI America and 
was utilized without further purification.  Cetyltrimethylammonium tosylate (CTAT) was 
purchased from Sigma and was recrystallized from ethanol-acetone to give a white 
powder.  The purified solid was stored at room temperature in a desiccator containing 
Drierite.  Several vesicle preparation methods were tested to determine if the extraction 
varied between the order and type of addition of the surfactant components.  Procedures 
for the other preparation methods can be found in the Experimental Section 2.4.2. 
Method 4 vesicles were formed by adding 9.90 mL of an aqueous SDBS solution 
(0.0203 M) directly to the bacterial cell pellet and stirring for 1 h at room temperature.  
30.0 mg of solid CTAT (0.0658 mmol) was added to the suspension and stirred for 1 h at 
room temperature.  
Vesicles were centrifuged for 5 min at 5,000 RPM and the supernatant was 
decanted.  The resulting colloidal supernatant, milky in appearance, was purified by SEC 
on Sephadex G-100 (Details in Chapter 2). 
Fractions were characterized for the presence of carbohydrate and protein using a 
phenol-sulfuric colorimetric assay42 and a modified procedure of the Pierce bicinchoninic 
acid (BCA) assay40, respectively (Details in Chapter 2).  
 
4.4.4  Gel Electrophoresis  
Purified vesicle samples and a molecular weight standard were mixed with 
loading buffer (5x SDS-PAGE gel loading buffer, 0.25M Tris-HCl, pH 6.8, 15% SDS, 
50% glycerol, 25% β-mercaptoethanol, and 0.01% bromophenol blue) and boiled for 10 
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min.  Samples were loaded onto an SDS-polyacrylamide gel (Tris-tricine 16.5% v/v) 
using Tris-tricine 1X as the running buffer and run for 4.5 h at 100 V on ice (Bio-Rad 
Model 200/2.0 power supply).   
 
4.4.5  Silver Staining 
After electrophoresis, the gels were incubated in a fixing solution (500 mL of 
38% ethanol and 25 mL glacial acetic acid) overnight on a shaker at room temperature.  
Gels were silver stained according to a modified procedure.43 The gel was transferred to 
100 mL of aqueous periodic acid (0.036 M) and washed for 5 min and rinsed with water 
for 30 min on a shaker four times.  The silver staining solution was prepared by adding 
4.0 mL of diluted silver nitrate (4.7 mmol) dropwise to Solution 1 (1 pellet sodium 
hydroxide, 25 mL water, 1.40 mL of 30% ammonium hydroxide).  If a brown color was 
present, additional ammonium hydroxide was added dropwise until the solution became 
clear and colorless.  The silver staining solution was brought to a final volume of 100 mL 
with water and the gel was incubated for 15 min with the solution on a shaker at room 
temperature.   
After staining, the gel was washed with water six times for 15 min each and 
incubated in a developing solution (95 µL formaldehyde 37% solution, 1 mL citric acid 







4.4.6  Protection Experiments 
 Vesicle-containing fractions were digested using 10 µL proteinase K (25 mg/mL) 
for a 500 µL sample incubated at 37°C.  Aliquots were taken after 18 h, 23 h, and 46 h.  
A control of the cell pellet was prepared by suspending the pellet in 1.0 mL of water.  
Proteinase K was added to the cell pellet suspension and a sample of whole cell lysate 
and incubated at 37°C.  Aliquots were taken after 18 h, 23 h, and 46 h and all samples 
were analyzed by electrophoresis and silver staining.  The original samples from the 
proteinase K digestion were also digested with trypsin (0.25%, Corning cellgro), where 
10 µL was added to 500 µL of sample and incubated at 37°C.  Aliquots were taken after 
18 h, 23 h, and 46 h and all samples were analyzed by electrophoresis and silver staining. 
 
4.4.7  Western Blotting 
Western blotting was performed under standard conditions.44  The nitrocellulose 
was rinsed with a PBS/Tween-20 solution 5 times for 15 min and then incubated with 
antigonococcal antisera (raised in a goat45) prepared in casein filler on a shaker for 2 h.  
The nitrocellulose was rinsed with a PBS 1X/Tween-20 solution five times for 15 min 
each and then incubated with donkey anti-goat HRP (Jackson ImmunoResearch 
laboratories Inc.) (1:100,000) secondary antibody solution prepared in casein filler on a 
shaker for 2 h. The nitrocellulose was rinsed with a PBS 1X/Tween-20 solution five 
times for 15 min each and then incubated with a standard Western blotting 





4.4.8  Proteomics Analysis 
Vesicle extracts were prepared from cell pellets formed from 20 mL, 40 mL, or 60 
mL of cells.  The remaining proteomics analysis was performed by Avantika Dhabaria.  
Known amounts of protein were spotted from these preparations in each lane of a one-
dimensional gel (Tris-HCl, 8-16% gradient).  Whole cell lysate was spotted in a fourth 
lane.  The gel was developed and stained with Coomassie blue stain (Sigma). 
Fifteen slices were cut from each lane and subjected to overnight in-gel tryptic 
digestion (13 ng/µL) using a standard procedure.46  The resulting peptides were extracted 
and injected into a capLC-MS/MS LTQ-orbitrap (ThermoFisher, San Jose, CA) as 
described elsewhere.47  Peptide and protein candidates were analyzed using the search 
program MASCOT 2.3 (Matrix Science, London, UK), and protein identifications were 
based on the number of associated tryptic peptides and the reliability of the peptide 
identifications.  Two protein databases were searched, one compiled of all Neisseria 
sequences from NCBInr (www.ncbi.nlm.nih.gov.com) and one comprised from only the 
proteins in NCBInr from the species N. gonorrhoeae.  Coverage Table 1.7 was used to 
remove any proteins that shared the same peptides and to generate the percent of 
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 Chapter 5: Drug Delivery Applications for Catanionic Surfactant 
Vesicles 
 
5 .1 Introduction 
5.1.1  Liposomes in Drug Formulation 
Liposomes were first loaded with biologically active substances in the early 
1970’s with the aim of using them as enzyme carriers in enzyme replacement therapy.1  
Since then, liposomal drugs have been approved by the Food and Drug Administration 
for clinical use, these approved drug products include Doxil and Myocet.2-6  Both drugs 
are liposomal formulations of the drug doxorubicin HCl (Figure 5.1, A), where the drug 
is encapsulated inside of liposomes.  In the case of Doxil, the surface of the liposome is 
coated with poly(ethylene glycol) (PEG), which acts as a protective coating to prevent 
clearance from the body (Figure 5.1, B). Daunorubicin (DaunoXome) is another example 




















   
       A                              B 
Figure 5.1. A) Chemical structure of doxorubicin.  B) PEGylated liposomes provide a 




All of these liposomal formulations are used to increase drug solubility, 
circulation time in the body, and decrease toxicity.  More importantly, drug efficacy is 
usually  improved since a higher concentration of the drug can be loaded into liposomes, 
which will cause fewer side effects.  For example, free doxorubicin drug causes 
cardiotoxicity in patients.7  However, liposomal formulations containing doxorubicin 
penetrate malignant tissue better while decreasing cardiotoxicity due to the reducing 
cardiac exposure to doxorubicin.7  Since the use of liposomes in drug delivery, additional 
liposomal formulations are being considered.  Many of these liposomal formulations have 
already been approved for clinical use (Table 5.1).3, 4, 8  Targeting agents have also been 
added to liposomes including carbohydrates, antibodies, folate, and peptides in order to 






Drug Name Formulation Status 
Doxil 
 
PEGylated liposomal doxorubicin 
 
Approved 















Ambisome Liposomal amphotericin B Approved 
DepoCyt Liposomal cytosine arabinoside Approved 
Visudyne Liposomal verteporfin Approved 
 




While liposomes are readily used in commercial drug applications, catanionic 
surfactant vesicles have yet to be utilized in the clinic as drug carriers.  In Chapters 3 and 
4, we showed that catanionic vesicles were loaded and characterized accordingly and 
could be used toward vaccine development.  Furthermore, catanionic vesicles were not 
toxic to animals when tested as vaccines by delivery vesicle intravenously or 
intraperitoneally.  We are interested in extending the role of catanionic vesicle systems 
for drug delivery applications in order to provide an alternative to their liposomal 
counterparts.  As mentioned before, catanionic vesicles can be easily prepared, are stable 
for years, and can be sterilized by autoclaving.  Furthermore, catanionic vesicles can be 
functionalized, allowing the ability for targeted drug delivery of a payload to specific 
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tissues.  Toward this goal, we studied catanionic vesicles loaded with the drug candidates 
doxorubicin, lutein, maytansine, and paclitaxel.  As for targeted delivery applications, we 
studied the cytotoxicity of doxorubicin-loaded catanionic vesicles functionalized with a 
targeting agent. 
 
5.2  Results and Discussion 
 In order for catanionic vesicles to be used in drug delivery, their loading 
efficiency and toxicity were studied.  In addition, drug loaded catanionic vesicles were 
functionalized with targeting agents toward cell lines that over express the receptor 
specific to the targeting agent.  Cell toxicity was compared between targeted and 
untargeted catanionic vesicles in order to determine if targeting increased drug uptake 
into cells (Figure 5.2).   
 
 




5.2.1  Doxorubicin Loaded Catanionic Surfactant Vesicles 
Catanionic surfactant vesicles were loaded with the drug doxorubicin in order to 
determine the retention of the drug over time.  Vesicles were loaded with 19 µg/mL 
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doxorubicin (33 µM) and an aliquot of the vesicle stock suspension was purified by SEC 
each day over 15 days.  Vesicles were 140 ± 10 nm in diameter and their size did not 
change over the 15 day timeframe, as determined by DLS.  These results indicated that 
catanionic vesicles loaded with doxorubicin are larger in size when compared to unloaded 
vesicles (~120 nm) and remained stable over time. 
Vesicle-containing fractions from each day were disrupted with ethanol and 
analyzed by UV/VIS.  Catanionic vesicle fractions purified on different days all showed 
complete retention of doxorubicin (Figure 5.3).  These results indicated that doxorubicin 
was loaded into catanionic vesicles and that these systems did not leak drug over time.    
 
 
Figure 5.3. Retention of doxorubicin over fifteen days in catanionic surfactant vesicles.  
Concentration of doxorubicin vesicle stock solution was 33 µM.  After purification by 




Since vesicles were proven to incorporate and retain doxorubicin at low 
concentrations, we wanted to determine the maximum loading of drug in vesicles.  
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Catanionic vesicle stock solutions were prepared containing 100 µg/mL (172 µM), 150 
µg/mL (259 µM), 200 µg/mL (345 µM), and 300 µg/mL (517 µM) of doxorubicin.   
When using high concentration stock solutions of doxorubicin (200 µg/mL and 300 
µg/mL), vesicles were formed but a red precipitate was observed.  Catanionic vesicles 
containing these concentrations were centrifuged and the precipitate was removed.  
Suspensions were purified by SEC and vesicle containing fractions eventually formed a 
red precipitate.  These result indicated that doxorubicin gradually leaked out of vesicles.  
If full retention of the drug is required, catanionic vesicles cannot be loaded with > 200 
µg/mL (345 µM) of doxorubicin, where a typical clinical dose of doxorubicin is 40-60 
mg/m2. 
Vesicles prepared with 100 µg/mL and 150 µg/mL doxorubicin stock solutions 
were stable over an extended period and did not precipitate drug, even after purification 
by SEC (Table 5.2).  These results showed that vesicles could be initially loaded with a 
maximum of 150 µg/mL of doxorubicin and after SEC contained 88 µg/mL of 











Initial Concentration  Concentration after SEC 
(µg/mL)    (µg/mL) (µM) 
100        75 138 
150        88 161 
200       165 303 
300       131 241 
 




 After determining the maximum loading of doxorubicin into catanionic vesicles, 
we were interested in studying the toxicity of these drug formulations.  As a benchmark 
for toxicity in humans, a typical dose of doxorubicin is 40-60 mg/m2.  For a typical 
person, this amount equates to a total dose of ~150-200 mg of doxorubicin.  The dose 
limiting toxicity (DLT) for doxorubicin is myelosuppression where nausea, vomiting, 
cardiotoxicity, and alopecia are other side effects.  In order to determine toxicity of 
doxorubicin loaded catanionic vesicles compared to the free drug, catanionic vesicles 
were loaded with doxorubicin and exposed to several different human cancer cell lines.  
The WST-1 cell proliferation assay was used to measure the cytotoxic effects of 
catanionic vesicles.  All toxicity studies were performed by the Translational Laboratory 
Shared Service (TLSS) personnel under the direction of Dr. Rena Lapidus at the 
University of Maryland School of Medicine Greenebaum Cancer Center.  
The cytotoxicity of catanionic vesicles was initially studied in the human 
hepatocellular carcinoma cell line HepG2.  These cells exhibit many of the characteristics 
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of normal liver cells.  Since many drugs are toxic to the liver, these cell lines are used for 
screening the cytotoxicity of new drugs.  HepG2 cells were used to study doxorubicin 
loaded catanionic vesicles to determine if the toxicity of the drug in vesicles was less than 
free drug.  The assay is based on the enzymatic cleavage of the tetrazolium salt of the 
WST-1 reagent to formazan by cellular mitochondrial dehydrogenases in living viable 
metabolically active cells.  The formazan product absorbs at 450 nm in a 
spectrophotometer. In this assay, mitochondrial enzymes of living cells break down the 
WST-1 dye (formazan derivative) so that the break-down product absorbs at a 
wavelength of 450 nm.  In other words, when cells are proliferating, formazan dye 
accumulates and the OD increases and when cells are not proliferating, the OD 
decreases..  
Results of toxicity studies in HepG2 cells yielded an IC50 of 51 µg/mL for DOX-
loaded vesicles and an IC50 of 0.16 µg/mL for free DOX (Figures 5.4 and 5.5).  These 
results indicated a 300-fold reduction in doxorubicin’s IC50 values compared to free drug.  









Figure 5.4. WST-1 cell proliferation assay on HepG2 cells treated with bare vesicles and 
doxorubicin loaded vesicles.  Cells were treated for 72 h.  Bare vesicles IC50 = 58 µg/mL 






Figure 5.5. WST-1 cell proliferation assay on HepG2 cells treated with doxorubicin.  
Free drug was incubated with cells for 72 h.  IC50 = 0.16 µg/mL. Toxicity studies 




Next, we wanted to determine the toxicity of bare vesicles (unloaded vesicles) in 
HepG2 cells.  The IC50 of bare catanionic vesicles was 58 µg/mL (Figure 5.4).  This IC50 
value indicated that bare and DOX-loaded catanionic vesicles have the same cytotoxicity.  
Therefore, the toxicity of DOX-loaded vesicles resulted from the catanionic vesicles 
themselves and not from DOX (Figure 5.6).  
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Figure 5.6. Free doxorubicin compared to doxorubicin loaded catanionic vesicles 




5.2.2  Targeted Doxorubicin Loaded Catanionic Surfactant Vesicles 
 Since DOX-loaded and unloaded catanionic vesicles have similar toxicity in the 
HepG2 cells, we wanted to study these systems with the addition of a targeting moiety.  
We studied targeted DOX-loaded catanionic vesicles to determine if toxicity increased as 
a result of uptake into cells via targeting agent-receptor binding (Figure 5.7).   
 
        
Figure 5.7.  Doxorubicin loaded untargeted and targeted catanionic vesicles incubated 




DOX-loaded catanionic vesicles were functionalized with C12-folate conjugate 
(Figure 5.8). Cytotoxicity of targeted DOX-loaded vesicles was determined in two 
different cell lines.  Cells were grown in folate-depleted media so that the folate in the 
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media did not compete with the folate-targeting moiety on vesicles.  A549 cells were 
chosen for initial studies because they have very low levels of the folate receptor.  
Cytotoxicity IC50 values of targeted unloaded vesicles and targeted-DOX vesicles in 
HepG2 cells were 7.2 µg/mL and 5.6 µg/mL, respectively (Figure 5.9).  Therefore, both 















C12-Folate conjugate  





Figure 5.9. WST-1 cell proliferation assay on A549 cells treated with folate targeted 
catanionic vesicles.  Cells were treated for 72 h.  Folate vesicles IC50 = 7.2 µg/mL, 
Folate-DOX vesicles IC50 = 5.6 µg/mL. Toxicity studies performed by TLSS at UMB. 
 
 
Next, we wanted to determine the cytotoxicity of these systems when incubated in 
IGROV-1 cells.  These cells were chosen because they highly express the folate receptor.  
Cytotoxicity IC50 values of targeted unloaded vesicles and targeted-DOX vesicles were 
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3.4 µg/mL and 2.2 µg/mL, respectively (Figure 5.10).  These results indicated that 
targeted vesicles were not more toxic when incubated with cells that over express the 
specific receptor. 
 
Figure 5.10. WST-1 cell proliferation assay on ovarian IGROV-1 cells, which over 
express folate, treated with folate targeted catanionic vesicles.  Cells were treated for 72 
h.  Folate vesicles IC50 = 3.4 µg/mL, Folate-DOX vesicles IC50 = 2.2 µg/mL.  Toxicity 




Results from toxicity studies with catanionic vesicles did not show increased 
toxicity of targeted catanionic vesicles.  However, there could be several explanations as 
to why toxicity did not increase: 1) catanionic vesicles were not loaded with enough 
targeting agent or 2) catanionic vesicles were not taken up by cells.  In order to study the 
latter possibility, future work will be devoted to determine whether catanionic vesicles 
enter cells.  Catanionic vesicles will be loaded with a dye and functionalized with a 
targeting agent.  Fluorescently labeled catanionic vesicles will be incubated with cells 
and studied by microscopy to observe the rate at which catanionic vesicles with and 









5.2.3  Lutein Loaded Catanionic Surfactant Vesicles 
Incorporation of the carotenoid lutein (Figure 5.12) into catanionic surfactant 
vesicles was studied for potential use is vesicle-based eye drops for the treatment of eye 
diseases.  The carotenoid lutein is believed to play a role in the prevention of age-related 
macular degeneration because of its presence in the neural retina of the human eye.41  
Unfortunately, lutein is very insoluble in aqueous solvents used in eye drops and is only 
soluble in organic solvents (i.e. methylene chloride).  Due to the soft nature of catanionic 
vesicles, these systems offer a convenient way to incorporate carotenoids into vesicles for 
eye drop technology.  Lutein was expected to insert into the vesicle bilayer of catanionic 
vesicles similar to their insertion into liposomes (Figure 5.14).42  Delivery of lutein 




















Lutein was added to dry surfactants and stirred in water.  While the solution 
became opalescent, indicating that vesicles formed, there was a yellow precipitate from 
lutein.  Successful incorporation of lutein into catanionic vesicles was eventually 
achieved after repeated sonication of vesicles in a water bath sonicator during vesicle 
formation.  After purification by SEC, vesicle-containing fractions had hydrodynamic 
radii of 100 ± 2 nm and appeared yellow in color, indicating that lutein was incorporated 
into the bilayer leaflet.  In addition, the top of the column was yellow in color, which 
indicated that any unincorporated lutein was insoluble could not be collected in later 
fractions.  Ethanol was added to vesicle-containing fractions from SEC in order to 
measure the amount of incorporated lutein by UV/VIS. Unfortunately, after lutein 
precipitated after the addition of ethanol.  This result indicated that vesicles were 
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disrupted and released the lutein, which is sparingly soluble in ethanol and water.  
Therefore, the amount of lutein in catanionic vesicles could not be quantitatively 
determined due to the insolubility of lutein after vesicle disruption.  These studies will be 
continued with disruption of vesicles with other solvents that also solubilize lutein.  For 
example, we have shown that catanionic vesicles can be disrupted by THF and lutein is 
highly soluble in THF.  Therefore, after disruption of vesicle-containing fractions with 
THF, the absorbance will be measured by UV/VIS to determine the amount of lutein 
incorporated into catanionic vesicles.    
 
5.2.4  Maytansine Loaded Catanionic Surfactant Vesicles 
Maytansine is an extremely toxic drug that is insoluble in water and most solvents 
(Figure 5.14).  Catanionic vesicles were loaded with the neutral hydrophobic drug 
maytansine in the hope that the drug could be solubilized and incorporated for drug 
delivery.  Maytansine was solubilized in THF and then added during vesicle formation.  
This solubilization was required in order for maytansine to dissolve so that the drug could 
be incorporated into catanionic vesicles.  Vesicles had a hydrodynamic radius of 126 ± 3 
nm and were purified by SEC.  All fractions were disrupted with ethanol and measured 
by UV/VIS.  Unfortunately, maytansine does not contain a good chromophore (Figure 
5.14).  Maytansine has an absorbance at 290 nm, which is close to the absorbance of the 
surfactants used in our catanionic vesicles.  UV/VIS of the vesicle-containing fraction 
showed a peak at 290 nm and was compared to bare vesicle containing fractions (Figure 
4.15).  It was difficult to quantitatively determine incorporation of the drug since the 
absorbance of maytansine and the surfactants absorb light in the same region.  For this 
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reason, a drug should be modified with a fluorescent tag so that incorporation into 

















           Maytansine  





Figure 5.15.  Absorbance of a maytansine analogue and maytansine loaded vesicle 








5.2.5  Paclitaxel Loaded Catanionic Surfactant Vesicles 
 Since the lack of a chromophore made it difficult to characterize it loading in 
catanionic vesicles, vesicles were loaded with a drug containing a fluorescent label.  
Paclitaxel fluorescein derivative (Figure 5.16) was added to vesicles prepared with dry 
surfactants and water.  These vesicles formed but did not yield yellow suspensions.  Due 
to the insolubility of paclitaxel, the drug was not incorporated during vesicle formation.  
Therefore, a solution of SDBS was used to solubilize paclitaxel by incorporating the drug 
into the hydrophobic region of micelles.  Then, solid CTAT was added, and yellow 
catanionic vesicles formed.  After purification by SEC, vesicle-containing fractions 
remained yellow in color.  These results indicated the presence of paclitaxel within 
catanionic vesicles, likely by the initial incorporation of the drug into micelles followed 
by incorporated into the bilayer leaflet after the addition of the second surfactant.  
Fractions were disrupted with ethanol and their absorbance was measured at 445 nm.  
Results of UV/VIS show that paclitaxel conjugate was successfully incorporated in 




















Pacitaxel fluorescein derivative  






Figure 5.17. Absorbance of paclitaxel loaded vesicles at 445 nm. After purification by 




5.3  Conclusions 
 Catanionic vesicles can be loaded with drug molecules and functionalized with 
targeting agents.  Catanionic vesicles loaded with doxorubicin showed low toxicity in the 
presence of normal liver cells.  Catanionic vesicles could be used for drug delivery of 
doxorubicin similar to the liposomal formulation Doxil.  Targeted catanionic vesicles did 
not increase toxicity of drug-loaded vesicles, but further studies will be performed in 
order to increase the targeting agent and to determine whether catanionic vesicles are 
incorporated into cells. We have also shown incorporation of other drugs into catanionic 
vesicles.  Fluorescently labeled drugs allow for better characterization in catanionic 





5.4  Experimental 
 Cell studies and animal work were preformed by the Translational Laboratory 
Shared Service (TLSS) personnel under the direction of Dr. Rena Lapidus at the 
University of Maryland School of Medicine Greenebaum Cancer Center. 
 
5.4.1  Doxorubicin 
To prepare doxorubicin-loaded vesicles for release studies, an aqueous solution of 
33 µM doxorubicin (Figure 5.1, A) was prepared.  To increase solubility of doxorubicin, 
the solution was sonicated in a water bath until full dissolution.  Then, 70.0 mg of SDBS 
(0.200 mmol) and 30.0 mg of CTAT (0.0658 mmol) was weighed into the vial followed 
by the addition of 9.90 mL of the doxorubicin solution and stirring for 60 min.  Vesicles 
were purified from free drug by SEC and analyzed by UV/VIS.  A 0.5 mL portion of 
each vesicle fraction was transferred to an empty vial where 0.5 mL absolute ethanol was 
added to the sample to prevent light scattering during absorption measurements.  The 
samples were vortexed and the absorbance was measured at 480 nm. 
Doxorubicin-loaded vesicles for toxicity studies were carried out under sterile 
conditions using aseptic technique in a biosafety cabinet.  All vials were autoclaved and 
all buffer solutions were initially sterile or were sterilized by filtration through a 0.2 µm 
filter.  Vesicle solutions were prepared using phosphate-buffered saline (PBS) 1X buffer.  
First, the PBS 1X was degassed in vacuo for 15-20 min.  Then 172 µM, 259 µM, 345 
µM, and 517 µM solutions of doxorubicin were prepared with the sterile degassed PBS 
1X. Then, 70.0 mg of SDBS (0.200 mmol) and 30.0 mg of CTAT (0.0658 mmol) was 
weighed into a sterile vial followed by the addition of 9.90 mL of the doxorubicin 
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solution and stirring for 60 min.  For doxorubicin-folate vesicles, 1 mg of C12-folate 
amide was prepared by Dr. Matthew Hurley and was added to the vesicle suspension and 
stirred overnight.  Vesicles were purified from free drug by SEC using degassed PBS 1X 
as the elution buffer. 
 
5.4.2  Lutein 
Lutein was recrystallized from dichloromethane/hexanes and was obtained from 
Dr. Frederick Khachik at the University of Maryland.  The purity was checked by 
UV/VIS absorbance at 446 nm.  Lutein was weighed directly into a vial containing SDBS 
and CTAT.  During vesicle formation, the suspension was sonicated every 10 min for 30 
s.  The sample was purified by SEC.  Vesicle-containing fractions were cloudy and 
appeared yellow in color. 
 
5.4.3  Maytansine 
To prepare maytansine vesicles, maytansine was dissolved in THF (5.1 mg/ mL) 
and was obtained from ImmunoGen, Inc.  A 196 µL (1.00 mg) aliquot of the solution was 
added to a vial containing 70.0 mg of SDBS (0.200 mmol) and 30.0 mg of CTAT (0.0658 
mmol).  Then, 9.90 mL of water was added and stirred for 60 min.  Vesicles were 
purified from free drug by SEC and analyzed by UV/VIS.  A 0.5 mL portion of each 
vesicle fraction was transferred to an empty vial where 0.5 mL absolute ethanol was 
added to the sample to prevent light scattering during absorption measurements.  The 




5.4.4  Paclitaxel 
To prepare paclitaxel vesicles, 0.5 mg of paclitaxel was dissolved in 9.90 mL 
(0.200 mmol) of an SDBS solution (7.07 mg/mL), which was obtained from Dr. Iwao 
Ojima at SUNY, Stony Brook.  The solution was stirred for 60 min.  Then 30.0 mg of 
CTAT (0.0658 mmol) was added and stirred for 60 min.  Vesicles were purified from 
free drug by SEC and analyzed by UV/VIS.  A 0.5 mL portion of each vesicle fraction 
was transferred to an empty vial where 0.5 mL absolute ethanol was added to the sample 
to prevent light scattering during absorption measurements.  The samples were vortexed 
and the absorbance was measured at 445 nm.   
 
5.4.5 Addendum 
 Targeted vesicles were added to A549 and IGROV-1 cells and cell proliferation 
was followed over 102 h. Figure A.2.23 shows that folate overexpressed cells (IGROV-1) 
are much more sensitive to folate vesicles than A549 cells.  The effect of folate-empty 
and folate –doxorubicin vesicles were equal in both cell lines.  This date suggests that 
folate-targeting of vesicles is successful when incubated with cells that overexpress the 
corresponding receptor.  Therefore, the previously reported IC50 values of folate-
doxorubicin vesicles should be measured at different incubation times in order to 





Figure 5.18. Time dependence of A549 and IGROV-1 cells in the presence of targeted 
catanionic vesicles.  When 50 µg/mL of folate-targeted vesicles were added to A549 
cells, the cells continued to proliferate. When 50 µg/mL of DOX-folate-targeted vesicles 
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Appendix I:  Chemistry Performed at the Surface of Catanionic 
Surfactant Vesicles 
 
A.1  Introduction 
 Surfactants are often used as solubilizing agents for hydrophobic molecules by 
incorporation of molecules within the hydrophobic cavity of micelles.1  Furthermore, 
surfactants have been utilized for chemical reactions between hydrophobic molecules in 
aqueous solvents.  In such systems, reagents associate in the internal hydrophobic region 
of a micelle, causing close interactions between the reactive species.  In addition, 
colloidal surfactant solutions are also used to increase the rate of these reactions by 
forcing molecules into close proximity.2  
Others have proposed using surfactant molecules to perform “green chemistry” in 
which the solvent used is water.  Such systems would replace the copious amounts of 
organic solvents used each year.3-7  Well-known reactions, such as Suzuki–Miyaura 
coupling, ring closing metathesis, and Stille coupling have achieved success within 
micelles.4, 5, 7   
 Surfactants are also used a stabilizing agents in aqueous solvents for molecules 
that are reactive with water.  For example, curcumin normally undergoes alkaline 
hydrolysis in water (Figure A.1, A).  Wang et al. reported incorporation of curcumin into 
micelles, which stabilized curcumin enough to determine the pKa of phenolic protons.8  
This indicated that the hydrophobic portion is associated with surfactant tails and the 
phenolic protons protrude from the micelle and are accessible for titration with base 




        A                    B 
Figure A.1. Chemical structure of curcumin and orientation in micelles.  The keto-enol 




Based on the understanding of how micelles solubilize hydrophobic molecules, 
we anticipated that chemistry could be performed using catanionic surfactant vesicles to 
selectively add or remove specific functional groups to molecules loaded in vesicles 
(Scheme A.1).  Rather than chemistry occurring within the aqueous internal compartment 
of vesicles, molecules associated with the lipid bilayer would undergo chemistry on the 
portions protruding from the vesicle surface.  The advantage of using catanionic vesicle 
systems rather than micelle forming surfactant mixtures is their robust nature.  Therefore, 
catanionic vesicles provide another “green chemistry” alternative approach to synthetic 
routes.  Furthermore, this work treats catanionic surfactant vesicles as protecting groups, 
where reactions could only take place on the portion of the molecule sticking out of the 
vesicles, leaving embedded functional groups untouched (Figure A.2). 
 






   
         Protected functional groups                       Selective reaction 




The purpose of this study was 1) to perform base hydrolysis on a lipid dye loaded 
in catanionic surfactant vesicles and 2) to study acid-base equilibrium reactions with 
chemical indicators loaded in vesicles.    
 
A.2  Results and Discussion 
A.2.1  Hydrolysis of Carboxyfluorescein-Lipid Dye from SDBS-rich Vesicles 
The cleavage of lipid-dye conjugates embedded in vesicles with NaOH was tested 
in order to show the promise of performing chemistry at the surface of intact catanionic 
vesicles (Scheme A.2).  SDBS-rich vesicles were loaded with the fluorescent dye 
carboxyfluorescein (CF) containing a phospholipid moiety.  An anionic dye was 
specifically chosen for use in SDBS-rich vesicles to prevent electrostatic interactions 
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Scheme A.2. Hydrolysis reaction of CF-lipid in catanionic vesicles via NaOH.  Addition 
of NaOH cleaves the two phospholipid ester groups, freeing the chromophore from the 




After purification of CF-lipid vesicles by SEC, vesicle-containing fractions were 
separated into two aliquots: one serving as the control for unreacted dye and the second 
for monitoring the hydrolysis reaction.  NaOH was added to the vesicle sample until the 
pH reached 10.  Immediately after the addition of base, the vesicle solution turned pink in 
color, which is consistent with the dianion form of CF (Scheme A.3).  After 24 h, vesicles 
were neutralized with HCl, where the colloidal solution returned yellow.  This color 
change indicated the reversible deprotonation of the phenolic proton under basic 









λmax = 453 nm, 472 nm λmax = 490 nm
Carboxyfluorescein monoanion     Carboxyfluorescein dianion  
Scheme A.3. CF monoanion and dianion chemical structures.  The neutral and 
monoanion are both yellow in color, while the dianion is pink.  The absorbance of the 




Both unreacted and reacted samples were purified a second time by SEC to 
separate any hydrolyzed dye from vesicles.  The absorbance of all SEC fractions was 
measured by UV-VIS.  For reacted vesicles, the chromophore was present in later 
fractions (Figure A.3).  This result indicated that CF-lipid dye was cleaved from the 
surface of vesicles, as predicted (Scheme A.2).  The same sample also showed the 
presence of chromophore in the vesicle-containing fractions.  This result indicated that 
the vesicles retained a portion of the unreacted lipid-dye.  Unreacted vesicles only 
showed absorbance in vesicle-containing fractions and no absorbance in later fractions.  
This result indicated that all CF-lipid was retained in untreated vesicles and the 
hydrolysis reaction did not occur.   
Ideally, the absorbance of the vesicle-containing fractions would be far lower in 
absorbance than the unreacted samples.  However, before purification, the reacted vesicle 
suspension was noticeably more intense in color, which indicated the presence of more 
dye.  Therefore, since the two suspensions after purification were comparable in 






Figure A.3. Purification of CF-lipid vesicles reacted with NaOH and unreacted.  Vesicles 




A.2.2  Surfactant Vesicles as Chemical Indicators 
After observing a color change of CF-lipid dye loaded in vesicles following the 
addition of base, the loading of a chemical indicator without a lipid tail into vesicles was 
studied.  We were interested in the ability to show that certain protons remain accessible 
at the surface of vesicles and can be deprotonated with base, even after their loading into 




Scheme A.4.  Deprotonation of protons at the surface of catanionic surfactant vesicles. 
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To test our hypothesis, catanionic vesicles were loaded with phenol red, a dye that 
changes from yellow to fuchsia under neutral to basic conditions, respectively (Scheme 
A.5).  By loading vesicles with phenol red and then adjusting the pH, one can determine 





Yellow (pH < 6.8)
O O
SO3
Fucshia (pH > 8.2)  
           Phenol red monoanion              Phenol red dianion  
     
Scheme A.5. Phenol red monoanion and dianion chemical structures.  The monoanion is 







Scheme A.6. Phenol red loaded in CTAT-rich vesicles.  Vesicles appear yellow in color 




SDBS-rich and CTAT-rich vesicles were loaded with the chemical indicator 
phenol red.  Only CTAT-rich vesicles (cationic) were yellow in color following 
purification by SEC.  This result indicated that anionic dye had been retained within 
CTAT-rich vesicles, which contain a positive surface charge.  SDBS-rich vesicles 
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(anionic) did not retain the dye because of the electrostatic repulsion between the anionic 
phenol red with the excess anionic surfactant.   
For the CTAT-rich SEC fractions, NaOH was added and previously yellow 
fractions turned pink in color (Figure A.4), indicating that deprotonation occurred to form 
the dianion (Scheme A.5).  After vesicles were reacidified with HCl, the color returned to 





Figure A.4. CTAT-rich vesicles containing phenol red after SEC purification.  A) All 
fractions are yellow in color from the monoanion at pH 7.  B) After addition of NaOH, all 
fractions turned fuchsia in color, indicating the presence of the dianion in solution.  
Vesicle-containing fractions incorporated phenol red, leaving the acidic proton accessible 
for the acid-base reaction.   
 
 
 While phenol red is lipophilic, it is also charged and can therefore orient itself 
either completely within the bilayer or associate itself with the surfactant head groups.  
Since CTAT-rich vesicles loaded with phenol red changed color at pH 10, phenol red is 
not completely embedded within the bilayer, but the phenolic proton must be protruding 
for vesicles (Scheme A.4).  The reversibility of the reaction within vesicles may be used 
for studying catanionic vesicles in vivo.  For example, uptake of catanionic vesicles 
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loaded with various chemical indicators offers the visualization of these vesicle systems 
as they enter different pH environments. 
 
A.3  Conclusions 
 Catanionic vesicles can be used to perform chemical reactions on molecules and 
also show potential toward protecting group chemistry.  The ability to perform chemical 
reactions on only the outer leaflet of the vesicle provides the ability to determine how 
much material is incorporated within the inner leaflet of vesicles (Scheme A.7).  
Furthermore, this allows the possibility to use catanionic vesicles as possible protecting 
groups where a reaction could be selective due to the orientation of the molecule inside of 
the vesicle bilayer (Figure A.5). 
 





   
 
Figure A.5. Catanionic surfactant vesicles as protecting groups.  For example, lutein 




A.4  Experimental 
The lipid dye 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(carboxyfluorescein) (ammonium salt) (CF) was purchased from Avanti Polar Lipids, 































A.4.1  Hydrolysis of Dye from SDBS-rich Vesicles  
An aliquot of CF-lipid was dried in vacuo and then dissolved in ethanol.  To the 
sample, 0.2 M NaOH was added until the pH reached 11 and then was stirred at room 
temperature.  The hydrolysis reaction was monitored by thin TLC using 65:30:5 
CH3Cl:MeOH:H2O as the solvent to determine the progress of the reaction.  Lipid 
components were detected by TLC using iodine.  
SDBS-rich vesicles were prepared with CF-lipid (Figure 4).  The dye was loaded 
into vesicles of opposite charge so that cleaved dye would not reassociate with the vesicle 
surface by electrostatic interactions.  A 25 µL aliquot (0.125 mg, 0.110 µmol) of CF-lipid 
dye in chloroform was added to the solid surfactants, 70.0 mg (0.200 mmol) SDBS and 
30.0 mg (0.0658 mmol) CTAT.  The sample remained open until the solvent evaporated, 
followed by the addition of 9.9 mL of water and stirring for 1 h at room temperature.  
Based on earlier studies, vesicles prepared via this method have CF-lipid dye decorated 
within the outer and inner vesicle bilayer (Scheme A.1).   
Vesicles were purified by SEC to remove any excess lipid dye prior to treatment 
with base.  Unassociated lipid dye was retained on the column.  Since the lipid dye is 
insoluble in water, the column was washed with a solution of SDBS (7.07 mg/mL) to 
remove the dye before further purifications.  The pH of all SEC fractions was increased 
to a pH of 10 by the dropwise addition of 0.2 M NaOH.  Vesicles were stirred at room 
temperature overnight.  Vesicles were purified a second time by SEC to separate any 
cleaved dye from vesicles.  Similarly, the control was purified a second time by SEC.     
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A 0.5 mL portion of ethanol was added to each 0.5 mL fraction from SEC to 
break up vesicles and prevent light scattering.  The absorbance was monitored by 
UV/VIS at 500 nm for CF-lipid dye.    
 
A.4.2  Phenol Red Vesicles 
 A 7.05 µM (0.125 mg/mL) solution of phenol red was prepared in water and 
sonicated until all of the dye dissolved.  Then, 9.9 mL (3.49 µmol) of the dye solution 
was added to 70.0 mg (0.200 mmol) SDBS and 30.0 mg (0.0658 mmol) to form SDBS-
rich vesicles and 70.0 mg (0.154 mmol) CTAT and 30.0 mg (0.0861 mmol) to form 
CTAT-rich vesicles.  The suspensions were stirred at room temperature for 1 h followed 
by purification by SEC.  Since SDBS-rich vesicle-containing fractions did not contain 
phenol red, only CTAT-rich vesicles were used as follows.   
 Dropwise addition 0.2 M NaOH was added to each SEC fraction until the pH 
turned to 10, which was determined by pH paper.  To determine the reversibility of the 
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